

REFINITIV

DELTA REPORT

10-Q

ACHC - ACADIA HEALTHCARE COMPANY

10-Q - MARCH 31, 2024 COMPARED TO 10-Q - SEPTEMBER 30, 2023

The following comparison report has been automatically generated

TOTAL DELTAS 1344

█	CHANGES	256
█	DELETIONS	547
█	ADDITIONS	541

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended **September 30, March 31, 2023** **2024**

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number: 001-35331

Acadia Healthcare Company, Inc.

(Exact name of registrant as specified in its charter)

Delaware

45-2492228

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer
Identification No.)

6100 Tower Circle, Suite 1000

Franklin, Tennessee 37067

(Address, including zip code, of principal executive offices)

(615) 861-6000

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$.01 par value	ACHC	NASDAQ Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer Accelerated filer Non-accelerated filer
Smaller reporting company Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

At **November 3, 2023** **May 2, 2024**, there were **92,216,476** **92,774,604** shares of the registrant's common stock outstanding.

ACADIA HEALTHCARE COMPANY, INC.

QUARTERLY REPORT ON FORM 10-Q
TABLE OF CONTENTS

PART I – FINANCIAL INFORMATION

Item 1.	<u>Financial Statements</u>	1
	<u>Condensed Consolidated Balance Sheets (Unaudited)</u>	1
	<u>Condensed Consolidated Statements of Operations Income (Unaudited)</u>	2
	<u>Condensed Consolidated Statements of Equity (Unaudited)</u>	3
	<u>Condensed Consolidated Statements of Cash Flows (Unaudited)</u>	4
	<u>Notes to Condensed Consolidated Financial Statements (Unaudited)</u>	5
Item 2.	<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	19 18
Item 3.	<u>Quantitative and Qualitative Disclosures About Market Risk</u>	30 26
Item 4.	<u>Controls and Procedures</u>	30 26

PART II – OTHER INFORMATION

Item 1.	<u>Legal Proceedings</u>	31 27
Item 1A.	<u>Risk Factors</u>	31 27
Item 2.	<u>Unregistered Sales of Equity Securities and Use of Proceeds and Issuer Repurchases of Equity Securities</u>	31 27

Item 5.5	31
Other Information	27
Item 6.	32
Exhibits	28
SIGNATURES	33
	29

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

Acadia Healthcare Company, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)

ASSETS	September		December			
	30,		31,			
	2023		2022			
	(In thousands, except share and per share amounts)		(In thousands, except share and per share amounts)			
Current assets:						
Cash and cash equivalents	\$ 99,591	\$ 97,649	\$ 77,303	\$ 100,073		
Accounts receivable, net	362,666	322,439	386,191	361,451		
Other current assets	241,218	86,037	147,312	134,476		

Total current assets	703,475	506,125	610,806	596,000
Property and equipment, net	2,145,5	1,952,0		
	99	45	2,376,059	2,266,610
Goodwill	2,225,9	2,222,8		
	62	05	2,261,026	2,225,962
Intangible assets, net	73,811	76,041	73,352	73,278
Deferred tax assets	2,850	2,950	2,777	6,658
Operating lease right-of-use assets	122,090	135,238	121,346	117,780
Other assets	72,431	92,697	71,881	72,553
Total assets	5,346,2	4,987,9		
	<u>\$ 18</u>	<u>\$ 01</u>	<u>\$ 5,517,247</u>	<u>\$ 5,358,841</u>
LIABILITIES AND EQUITY				
Current liabilities:				
Current portion of long-term debt	\$ 26,563	\$ 21,250	\$ 61,452	\$ 29,219
Accounts payable	149,874	104,723	156,130	156,132
Accrued salaries and benefits	122,264	125,298	118,005	141,901
Current portion of operating lease liabilities	26,242	26,463	26,815	26,268
Other accrued liabilities	539,947	110,592	119,911	532,261
Total current liabilities	864,890	388,326	482,313	885,781
Long-term debt	1,349,9	1,364,5		
	54	41	1,794,296	1,342,548
Deferred tax liabilities	70,450	92,588	15,527	1,931
Operating lease liabilities	104,873	116,429	103,352	100,808
Other liabilities	145,907	125,033	146,404	140,113
Total liabilities	2,536,0	2,086,9		
	74	17	2,541,892	2,471,181
Redeemable noncontrolling interests	97,582	88,257	109,333	105,686
Equity:				
Preferred stock, \$0.01 par value; 10,000,000 shares authorized, no shares issued	—	—		
Common stock, \$0.01 par value; 180,000,000 shares authorized; 91,204,474 and 89,913,659 issued and outstanding at September 30, 2023 and December 31, 2022, respectively	912	899		

Preferred stock, \$0.01 par value; 10,000,000 shares authorized, no shares issued	—	—
Common stock, \$0.01 par value; 180,000,000 shares authorized; 91,573,596 and 91,263,989 issued and outstanding at March 31, 2024 and December 31, 2023, respectively	916	913
Additional paid-in capital	2,637,6	2,658,4
	58	40
Retained earnings	73,992	153,388
	2,712,5	2,812,7
	62	27
Total equity	5,346,2	4,987,9
	\$ 18	\$ 01
	\$ 5,517,247	\$ 5,358,841
Total liabilities and equity		

See accompanying notes.

1

Acadia Healthcare Company, Inc.
Condensed Consolidated Statements of Operations Income
(Unaudited)

Three Months Ended				Nine Months Ended		Three Months Ended	
September 30,		September 30,		March 31,		2024	
2023	2022	2023	2022				2023
(In thousands, except per share amounts)							
(In thousands, except per share amounts)							

Revenue	666	2,18	1,93			
	750,	,73	5,93	5,10		
	\$ 334	\$ 2	\$ 8	\$ 4	\$	\$ 768,051
						704,267
Salaries, wages and benefits (including equity-based compensation expense of \$8,163, \$7,240, \$23,140 and \$21,745, respectively)	352	1,17	1,02			
	394,	,58	1,96	7,73		
	150	2	0	2		
Salaries, wages and benefits (including equity-based compensation expense of \$8,678 and \$7,629, respectively)					417,523	391,177
Professional fees	45,5	40,	130,	117,		
	40	367	468	718		
Supplies	27,1	25,	79,3	74,2		
	47	570	12	91		
Rents and leases	11,7	11,	34,8	33,7		
	31	339	80	80		
Other operating expenses	104,	88,	290,	255,		
	048	993	798	355		
Income from provider relief fund	(4,4	(7,6	(4,4	(16,		
	42)	56)	42)	206)		
Depreciation and amortization	33,3	29,	96,9	87,6		
	88	573	69	27		
Interest expense, net	20,7	18,	61,6	50,3		
	42	003	51	55		
Legal settlements expense	394,		394,			
	181	—	181	—		
Loss on impairment			8,69			
	—	—	4	—		
Transaction-related expenses	11,2	10,	26,7	18,3		
	47	859	92	81		
Transaction, legal and other costs					2,847	6,471

Total expenses	1,03	569	2,29	1,64		
	7,73	,63	1,26	9,03		
	2	0	3	3		
					669,207	618,624
(Loss) income before income taxes	(287	97,	(105	286,		
	,398)	102	,325)	071		
(Benefit from) provision for income taxes	(71,	24,	(29,	69,1		
	873)	056	907)	83		
Net (loss) income	(215	73,	(75,	216,		
	,525)	046	418)	888		
Income before income taxes					98,844	85,643
Provision for income taxes					20,074	19,085
Net income					78,770	66,558
Net income attributable to noncontrolling interests	(2,1	(1,9	(3,9	(4,8		
	85)	47)	78)	73)		
Net (loss) income attributable to Acadia Healthcare Company, Inc.	(217	71,	(79,	212,		
	\$,710)	\$ 099	\$ 396)	\$ 015		
(Loss) earnings per share attributable to Acadia Healthcare Company, Inc. stockholders:						
Net income attributable to Acadia Healthcare Company, Inc.					\$ 76,383	\$ 66,015
Earnings per share attributable to Acadia Healthcare Company, Inc. stockholders:						
Basic	(2.3	0.7	(0.8			
	\$ 9)	\$ 9	\$ 7)	\$ 2.37		
Diluted	(2.3	0.7	(0.8			
	\$ 9)	\$ 8	\$ 7)	\$ 2.31		
Weighted-average shares outstanding:						
Basic	91,1	89,	90,8	89,6		
	68	833	52	07		
Diluted	91,1	91,	90,8	91,6		
	68	723	52	68		
					91,363	90,101
					92,010	91,391

See accompanying notes.

Acadia Healthcare Company, Inc.
Condensed Consolidated Statements of Equity
(Unaudited)
(In thousands)

	Addit ional			Retained		Additional			
	Common	Paid-	Earnings	Stock	in	(Accumulated)	Common Stock	Paid-in	Retained
	Sh	Am	are	oun	Capit				
	s	t		al		Deficit)	Total	Shares	Amount
Balance at December 31,	89			2,63			2,51		
2021	,0	89		6,35			7,48		
	28	\$ 0	\$ 0	\$ 0	\$ (119,751)	\$ 9			
Common stock issued									
under stock incentive	63			3,74			3,74		
plans	3	7	2		—	9			
Repurchase of shares									
for payroll tax									
withholding, net of									
proceeds from stock				(15,		(15,			
option exercises	—	—	490)		—	490)			
Equity-based				7,92			7,92		
compensation expense	—	—	5		—	5			

Net income attributable					
to Acadia Healthcare				60,8	
Company, Inc.	—	—	—	60,837	37
Balance at March 31,	89	2,63		2,57	
2022	,6	89	2,52		4,51
	61	7	7	(58,914)	0
Common stock issued					
under stock incentive	11	3,14		3,14	
plans	3	1	7	—	8
Repurchase of shares					
for payroll tax					
withholding, net of					
proceeds from stock		(1,2		(1,2	
option exercises	—	—	75)	—	75)
Equity-based		6,58		6,58	
compensation expense	—	—	0	—	0
Net income attributable					
to Acadia Healthcare				80,0	
Company, Inc.	—	—	—	80,079	79
Balance at June 30, 2022	89	2,64		2,66	
	,7	89	0,97		3,04
	74	8	9	21,165	2
Common stock issued					
under stock incentive	10	3,06		3,06	
plans	1	1	6	—	7
Repurchase of shares					
for payroll tax					
withholding, net of					
proceeds from stock		(74		(74	
option exercises	—	—	0)	—	0)
Equity-based		7,24		7,24	
compensation expense	—	—	0	—	0
Net income attributable					
to Acadia Healthcare				71,0	
Company, Inc.	—	—	—	71,099	99

Balance at September 30, 2022	89	89	2,65	0,54	75	9	5	2,74	3,70	92,264	8
Common stock issued under stock incentive plans											
under stock incentive plans											
Repurchase of shares for payroll tax withholding, net of											
proceeds from stock option exercises											
Equity-based compensation expense											
Other											
Net income attributable to Acadia Healthcare Company, Inc.											
Balance at December 31, 2022	89	89	2,65	0,54	75	9	5	2,81	2,72	153,388	7
Common stock issued under stock incentive plans	1,03	9	1,19	2	—	11	2	1,20	1,192	1,039	—
Repurchase of shares for payroll tax withholding, net of											
proceeds from stock option exercises											
Equity-based compensation expense											
Other											
Net income attributable to Acadia Healthcare Company, Inc.											
66,015	15	—	66,015	15	—	—	—	66,015	66,015	66,015	66,015

Balance at March 31,	90	2,61	2,83							
2023	,9	91	9,28	9,60						
	53	0	9	219,403	2	90,953	910	2,619,289	219,403	2,839,602
Common stock issued under stock incentive plans	17		3,78		3,78					
	6	1	3	—	4	176	1	3,783	—	3,784
Repurchase of shares for payroll tax withholding, net of										
proceeds from stock option exercises			(2,0)		(2,0)					
	—	—	17)	—	17)	—	—	(2,017)	—	(2,017)
Equity-based compensation expense			7,34		7,34					
	—	—	8	—	8	—	—	7,348	—	7,348
Net income attributable to Acadia Healthcare Company, Inc.					72,2					
	—	—	—	72,299	99	—	—	—	72,299	72,299
Balance at June 30, 2023	91	2,62		2,92						
	,1	91	8,40	1,01						
	29	1	3	291,702	6	91,129	911	2,628,403	291,702	2,921,016
Common stock issued under stock incentive plans			1,55		1,55					
	76	1	3	—	4	76	1	1,553	—	1,554
Repurchase of shares for payroll tax withholding, net of										
proceeds from stock option exercises			(84)		(84)					
	—	—	3)	—	3)	—	—	(843)	—	(843)
Equity-based compensation expense			8,16		8,16					
	—	—	3	—	3	—	—	8,163	—	8,163
Other			382	—	382	—	—	382	—	382
Net loss attributable to Acadia Healthcare Company, Inc.					(21					
	—	—	—	(217,710)	0)	—	—	—	(217,710)	(217,710)
Balance at September 30, 2023	91	2,63		2,71						
	,2	91	7,65	2,56						
	05	\$ 2	\$ 8	\$ 73,992	\$ 2	91,205	912	2,637,658	73,992	2,712,562

Common stock issued under stock incentive plans	59	1	1,655	—	1,656
Repurchase of shares for payroll tax withholding, net of proceeds from stock option exercises	—	—	(798)	—	(798)
Equity-based compensation expense	—	—	9,149	—	9,149
Other	—	—	1,676	—	1,676
Net income attributable to Acadia Healthcare Company, Inc.	—	—	—	57,729	57,729
Balance at December 31, 2023	91,264	913	2,649,340	131,721	2,781,974
Common stock issued under stock incentive plans	310	3	4,099	—	4,102
Repurchase of shares for payroll tax withholding, net of proceeds from stock option exercises	—	—	(5,115)	—	(5,115)
Equity-based compensation expense	—	—	8,678	—	8,678
Net income attributable to Acadia Healthcare Company, Inc.	—	—	—	76,383	76,383
Balance at March 31, 2024	91,574	\$ 916	\$ 2,657,002	\$ 208,104	\$ 2,866,022

See accompanying notes.

Acadia Healthcare Company, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited)

	Nine Months Ended		Three Months Ended	
	September 30,		March 31,	
	2023	2022	2024	2023
	(In thousands)			
Operating activities:				
Net (loss) income	(75,41	216,88	\$ 8)	\$ 8
Adjustments to reconcile net (loss) income to net cash provided by operating activities:				
Net income	\$ 78,770	\$ 66,558	\$ 78,770	\$ 66,558
Adjustments to reconcile net income to net cash (used in) provided by operating activities:				
Depreciation and amortization	96,969	87,627	36,347	31,569
Amortization of debt issuance costs	2,485	2,440	1,016	824
Equity-based compensation expense	23,140	21,745	8,678	7,629
Deferred income taxes	(21,65	5)	20,176	17,476
Legal settlements expense	394,18	1	—	212
Loss on impairment	8,694	—	(4,094)	1,089
Other	1,423	2,422	(22,930)	(23,968)
Change in operating assets and liabilities, net of effect of acquisitions:				
Accounts receivable, net	(40,22	(35,53	(15,629)	(23,430)
Other current assets	7)	8)	(28,69	5)

Other assets	309	3,373	696	(1,436)
Accounts payable and other accrued liabilities	23,057	7,729	(403,340)	13,633
Accrued salaries and benefits	(3,038)	(8,831)	(25,024)	(30,386)
Other liabilities	17,723	10,303	6,749	2,114
Government relief funds		(32,61)		
	(4,442)	7)		
Net cash provided by operating activities	346,03	267,02		
	6	5		
Net cash (used in) provided by operating activities			(321,285)	44,408
Investing activities:				
Cash paid for acquisitions, net of cash acquired	(349)	—	(50,353)	—
Cash paid for capital expenditures	(285,4	(208,7		
	10)	92)	(142,410)	(66,525)
Proceeds from sale of property and equipment	633	1,784	9,056	409
Other	(1,925)	(6,802)	(907)	(794)
Net cash used in investing activities	(287,0	(213,8		
	51)	10)	(184,614)	(66,910)
Financing activities:				
Borrowings on long-term debt			350,000	—
Borrowings on revolving credit facility	40,000	—	160,000	40,000
Principal payments on revolving credit facility	(35,00	(85,00		
	0)	0)	(15,000)	—
Principal payments on long-term debt	(15,93	(13,28		
	8)	1)	(10,242)	(5,313)
Payment of debt issuance costs			(1,518)	—
Repurchase of shares for payroll tax withholding, net of proceeds from stock	(45,19			
option exercises	3)	(7,541)	(1,013)	(47,671)
Contributions from noncontrolling partners in joint ventures	2,538	13,178	2,280	1,655
Distributions to noncontrolling partners in joint ventures	(3,480)	(1,004)	(1,020)	—
Other	30	39	(358)	11
Net cash used in financing activities	(57,04	(93,60		
	3)	9)		
Net increase (decrease) in cash and cash equivalents		(40,39		
	1,942	4)		

Net cash provided by (used in) financing activities		483,129	(11,318)
Net decrease in cash and cash equivalents		(22,770)	(33,820)
Cash and cash equivalents at beginning of the period	133,81		
	97,649	3	100,073
Cash and cash equivalents at end of the period	\$ 99,591	\$ 93,419	\$ 77,303
	<u>\$ 99,591</u>	<u>\$ 93,419</u>	<u>\$ 77,303</u>
Effect of acquisitions:			
Assets acquired, excluding cash	\$ 6,766	\$ —	\$ 55,309
Liabilities assumed	(128)	—	(3,456)
Redeemable noncontrolling interest resulting from an acquisition	(6,289)	—	
Contingent consideration issued in connection with an acquisition			(1,500)
Cash paid for acquisitions, net of cash acquired	\$ 349	\$ —	\$ 50,353
	<u>\$ 349</u>	<u>\$ —</u>	<u>\$ 50,353</u>

See accompanying notes.

4

Acadia Healthcare Company, Inc.
Notes to Condensed Consolidated Financial Statements
September 30, 2023 March 31, 2024
(Unaudited)

1. Description of Business and Basis of Presentation

Description of Business

Acadia Healthcare Company, Inc. (the “Company”) develops and operates acute inpatient psychiatric facilities, specialty treatment facilities, comprehensive treatment centers (“CTCs”), residential treatment centers group homes, substance abuse facilities and facilities providing outpatient behavioral healthcare services to serve the behavioral health healthcare and recovery needs of communities throughout the United States (“U.S.”) and Puerto Rico. At September 30, 2023 March 31, 2024, the Company operated 253 258 behavioral healthcare facilities with approximately 11,100 11,300 beds in 39 38 states and Puerto Rico.

Basis of Presentation

The business of the Company is conducted through limited liability companies, partnerships and C-corporations. The Company's consolidated financial statements include the accounts of the Company and all subsidiaries controlled by the Company through its direct or indirect ownership of majority interests and exclusive rights granted to the Company as the controlling member of an entity. All intercompany accounts and transactions have been eliminated in consolidation.

The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for fair presentation of the Company's financial position and results of operations have been included. The Company's fiscal year ends on December 31 and interim results are not necessarily indicative of results for a full year or any other interim period. The condensed consolidated balance sheet at **December 31, 2022** **December 31, 2023** has been derived from the audited financial statements as of that date. The information contained in these condensed consolidated financial statements should be read in conjunction with the Company's consolidated financial statements and notes thereto for the fiscal year ended **December 31, 2022** **December 31, 2023** included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on **February 28, 2023** **February 28, 2024**. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.

Certain reclassifications have been made to the prior year to conform to the current year presentation.

2. Recently Issued Accounting Standards

In **November 2021**, **December 2023**, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update ("ASU") **2021-10**, **2023-09** "Government Assistance Income Taxes (Topic 832)" **740** ("ASU 2021-10") "Improvements to Income Tax Disclosures". ASU 2021-10 provides guidance **2023-09** is intended to **increase** **enhance** the transparency and decision usefulness of government assistance including the disclosure of (1) the types of assistance, (2) an entity's accounting for the assistance, and (3) the effect of the assistance on an entity's financial statements. ASU 2021-10 applies to all business entities except for not-for-profit entities within the scope of Topic 958, *Not-for-Profit Entities*, and employee benefit plans within the scope of Topic 960, *Plan Accounting—Defined Benefit Pension Plans*, Topic 962, *Plan Accounting—Defined Contribution Pension Plans*, and Topic 965, *Plan Accounting—Health and Welfare Benefit Plans* that account for a transaction with a government by applying a grant or contribution accounting model by analogy to other accounting **income tax disclosures**. This guidance (for example, a grant model within IAS 20, *Accounting for Government Grants and Disclosure of Government Assistance*, or Subtopic 958-605, *Not-For-Profit Entities—Revenue Recognition*). ASU 2021-10 is effective for fiscal years beginning after **December 15, 2021**, **December 15, 2024**, with early adoption permitted, and may be applied either prospectively or retrospectively. The Company **adopted** is currently evaluating the impact of ASU 2021-10 for the year ended December 31, 2022. See Note 9 – The CARES Act for additional information on the Company's accounting for government grants received.

In March 2020, the FASB issued ASU 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting” (“ASU 2020-04”). ASU 2020-04 provides optional guidance for a limited period of time to ease the potential burden in accounting for or recognizing the effects of reference rate reform on financial reporting and applies only to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued because of reference rate reform. ASU 2020-04 is effective as of March 12, 2020 through December 31, 2024. Entities may adopt ASU 2020-04 as of any date from the beginning of an interim period that includes or is subsequent to March 12, 2020 or prospectively from a date within an interim period that includes or is subsequent to March 12, 2020, up to the date that the financial statements are available to be issued. The Company adopted ASU 2020-04 for the quarter ended

March 31, 2023. See Note 11 – Long Term Debt for additional information on the Company’s accounting for the reference rate reform. There is no significant impact 2023-09 on the Company’s consolidated financial statements.

3. Revenue

Revenue is primarily derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care and residential treatment. The services provided by the Company have no fixed duration and can be terminated by the patient or the facility at any time, and therefore, each treatment is its own stand-alone contract.

Services ordered by a healthcare provider in an episode of care are not separately identifiable and therefore have been combined into a single performance obligation for each contract. The Company recognizes revenue as its performance obligations are completed. The performance obligation is satisfied over time as the customer simultaneously receives and consumes the benefits of the healthcare services provided. For inpatient services, the Company recognizes revenue equally over the patient stay on a daily basis. For outpatient services, the Company recognizes revenue equally over the number of treatments provided in a single episode of care. Typically, patients and third-party payors are billed within several days of the service being performed or the patient being discharged, and payments are due based on contract terms.

As the Company’s performance obligations relate to contracts with a duration of one year or less, the Company elected the optional exemption in Accounting Standards Codification (“ASC”) 606-10-50-14(a). Therefore, the Company is not required to disclose the transaction price for the remaining performance obligations at the end of the reporting period or when the Company

expects to recognize the revenue. The Company has minimal unsatisfied performance obligations at the end of the reporting period as its patients typically are under no obligation to remain admitted in the Company's facilities.

The Company disaggregates revenue from contracts with customers by service type and by payor.

The Company's facilities and services provided by the facilities can generally be classified into the following categories: acute inpatient psychiatric facilities; specialty treatment facilities; **comprehensive treatment centers ("CTCs")**; **CTCs**; and residential treatment centers.

Acute inpatient psychiatric facilities. Acute inpatient psychiatric facilities provide a high level of care in order to stabilize patients that are either a threat to themselves or to others. The acute setting provides 24-hour observation, daily intervention and monitoring by psychiatrists.

Specialty treatment facilities. Specialty treatment facilities include residential recovery facilities and eating disorder facilities. The Company provides a comprehensive continuum of care for adults with addictive disorders and co-occurring mental disorders. Inpatient, including detoxification and rehabilitation, partial hospitalization and outpatient treatment programs give patients access to the least restrictive level of care.

Comprehensive treatment centers. CTCs specialize in providing medication-assisted treatment in an outpatient setting to individuals addicted to opioids such as opioid analgesics (prescription pain medications).

Residential treatment centers. Residential treatment centers treat patients with behavioral disorders in a non-hospital setting, including outdoor programs. **setting.** The facilities balance therapy activities with social, academic and other activities.

The table below presents total revenue attributed to each category (in thousands):

	Three Months				Three Months Ended	
	Ended		Nine Months Ended		March 31,	
	September 30,		September 30,		2024	
	2023	2022	2023	2022	2024	2023
Acute inpatient psychiatric facilities	382,	340,	1,113,	984,22	\$ 406,422	\$ 361,811
Specialty treatment facilities	158,	145,	462,91	419,76	143,832	147,303
Comprehensive treatment centers	129,	106,	368,61	310,08	132,167	115,501
Residential treatment centers	79,5	73,3	240,77	221,03	85,630	79,652
Revenue	750,	666,	2,185,	1,935,	\$ 768,051	\$ 704,267
	\$ 334	\$ 732	\$ 938	\$ 104		

The Company receives payments from the following sources for services rendered in its facilities: (i) state governments under their respective Medicaid and other programs; (ii) commercial insurers; (iii) the federal government under the Medicare program administered by the Centers for Medicare and Medicaid Services (“CMS”) and other programs; and (iv) individual patients and clients.

The Company determines the transaction price based on established billing rates reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients and implicit price concessions. Contractual adjustments and discounts are based on contractual agreements, discount policies and historical experience. Implicit price concessions are based on historical collection experience. Most of the Company's facilities have contracts containing variable consideration. However, it is unlikely a significant reversal of revenue will occur when the uncertainty is resolved, and therefore, the Company has included the variable consideration in the estimated transaction price. Subsequent changes resulting from a patient's ability to pay are recorded as bad debt expense, which is included as a component of other operating expenses in the condensed consolidated statements of operations. Bad debt expense for the three and nine months ended September 30, 2023 March 31, 2024 and 2022 2023 was not significant.

The following table presents the Company's revenue by payor type and as a percentage of revenue (in thousands):

	Three Months Ended				Nine Months Ended				Three Months Ended			
	September 30,		September 30,		September 30,		September 30,		March 31,		March 31,	
	2023	2022	2023	2022	2023	2022	2023	2022	2024	2023	2024	2023
	Am	Am	Am	Am	Am	Am	Am	Am	Amount	Amount	Amount	Amount
	ou	ou	oun	oun	nt	nt	t	%	%	%	%	%
	nt	%	nt	%	t	%	t	%				
C	2	1	6	5								
o	1	9	2	9								
m	2	3	5	0								
m	, 2	, 2	, 2	, 3	, 2	, 2	, 3	, 3				
er	3 8	6 9	3 8	9 0								
ci	2 .	2 .	3 .	6 .								
al	\$ 8	3%	\$ 6	0%	\$ 0	6%	\$ 6	5%	\$ 196,017	25.5%	\$ 203,619	28.9%

	1	1	3	2								
M	1	0	3	9								
e	7	1	5	3								
di	,	1	,	1	,	1						
c	3	5	2	5	8	5	3	5				
ar	4	.	4	.	1	.	3	.				
e	8	6%	6	2%	9	4%	9	2%				
									109,388		108,640	15.4 %
									1			
									,			
									4	3	1	9
M	0		4			5		7				
e	0		3			6		0				
di	,	5	,	5	,	5	,	5				
c	4	3	0	1	7	2	5	0				
ai	8	.	6	.	6	.	9	.				
d	3	4%	7	5%	6	9%	1	2%			436,422	56.9 %
S	1		2			5		5			364,306	51.8 %
el	5		0			2		8				
f-	,		,		,	,		,				
P	5	2	0	3	0	2	3	3				
a	2	.	1	.	2	.	9	.				
y	4	1%	3	0%	6	4%	0	0%			16,427	2.1 %
									1	2		
									4	8	5	1
									,	,	,	,
O	6	0	7	1	9	0	8	1				
th	5	.	8	.	9	.	1	.				
er	1	6%	0	3%	7	7%	8	1%			9,797	1.3 %
									2	1		
									,	,		
R	7		6			1		9				
e	5		6			8		3				
v	0	1	6	1	5	1	5	1				
e	,	0	,	0	,	0	,	0				
n	3	0	7	0	9	0	1	0				
u	3	.	3	.	3	.	0	.				
e	\$ 4	0%	\$ 2	0%	\$ 8	0%	\$ 4	0%	\$	768,051		100.0 %
											\$ 704,267	
												100.0 %

4. Earnings Per Share

The following table sets forth the computation of basic and diluted earnings per share for the three and nine months ended **September 30, 2023** **March 31, 2024** and **2022** **2023** (in thousands, except per share amounts):

	Three Months Ended		Nine Months Ended		Three Months Ended	
	September 30,		September 30,		March 31,	
	2023	2022	2023	2022	2024	2023
Numerator:						
Net (loss) income attributable to Acadia Healthcare Company, Inc.	71,		212			
Acadia Healthcare Company, Inc.	(217	09	(79,	,01		
	<u>\$,710)</u>	<u>\$ 9</u>	<u>\$ 396)</u>	<u>\$ 5</u>		
Net income attributable to Acadia Healthcare Company, Inc.					\$ 76,383	\$ 66,015
Denominator:						
Weighted average shares outstanding for basic earnings per share	89,					
outstanding for basic earnings per share	91,1	83	90,	89,		
	68	3	852	607		
Effects of dilutive instruments	1,8		2,0			
	—	90	—	61	647	1,290
Shares used in computing diluted earnings per common share	91,					
Shares used in computing diluted earnings per common share	91,1	72	90,	91,		
	68	3	852	668		
	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u>92,010</u>	<u>91,391</u>
(Loss) earnings per share attributable to Acadia Healthcare Company, Inc. stockholders:						

Earnings per share attributable to

Acadia Healthcare

Company, Inc. stockholders:

Basic	(2.3)	0.7	(0.8)	2.3	\$ 9)	\$ 9	\$ 7)	\$ 7	\$ 0.84	\$ 0.73
Diluted	(2.3)	0.7	(0.8)	2.3	\$ 9)	\$ 8	\$ 7)	\$ 1	\$ 0.83	\$ 0.72

Approximately

For the three and nine months ended September 30, 2023, approximately **0.5** **0.3** million and 0.8 million, respectively, outstanding shares of restricted stock and shares of common stock issuable upon exercise of outstanding stock option awards have been included in the calculation of weighted-average shares outstanding-diluted. These shares are excluded from the calculation of diluted earnings per share in the condensed consolidated statement of operations because the net loss for both the three and nine months ended September 30, 2023 causes such securities to be anti-dilutive.

Approximately 0.4 million shares of common stock issuable upon exercise of outstanding stock option awards were excluded from the calculation of diluted earnings per share for both the three and nine months ended September 30, 2023, respectively, because their effect would have been anti-dilutive. Approximately 0.1 million and **0.6** **0.5** million shares of common stock issuable upon exercise of outstanding stock option awards were excluded from the calculation of diluted earnings per share for the three and nine months ended September 30, 2022, March 31, 2024 and 2023, respectively, because their effect would have been anti-dilutive.

7

5. Acquisitions

The Company's **acquisition** strategy is to acquire and develop behavioral healthcare facilities and improve operating results within its facilities and its other behavioral healthcare operations.

On **November 7, 2022** **February 22, 2024**, the Company completed the acquisition of four CTCs located in Georgia from Brand New Start Treatment Centers.

In July 2023, the Company signed a definitive agreement to acquire **acquired** substantially all of the assets of Turning Point Centers ("Turning Point"), a 76-bed specialty provider of substance use disorder and primary mental health treatment services that supports the Salt Lake City, Utah, metropolitan market. Turning Point provides a full continuum of treatment services, including residential, partial hospitalization and intensive outpatient services. The transaction is expected to close by the end of 2023.

Goodwill

The changes in goodwill are as follows (in thousands):

Balance at January 1, 2022		\$ 2,199,937
Increase from acquisitions		9,488
Adjustments related to 2021 acquisitions		8,761
Increase from contributions of redeemable noncontrolling interests		4,619
Balance at December 31, 2022		2,222,805
Increase from acquisitions		336
Increase from contributions of redeemable noncontrolling interests		2,821
Balance at September 30, 2023		\$ 2,225,962

Transaction-related expenses

Transaction-related expenses represent costs primarily related to legal, accounting, termination, restructuring, management transition, acquisition and other similar costs. Transaction-related expenses comprised the following costs for the three and nine months ended September 30, 2023 and 2022 (in thousands):

	Three Months Ended September			
	30,		Nine Months Ended September 30,	
	2023	2022	2023	2022
Legal, accounting and other acquisition-related costs	\$ 4,196	\$ 2,020	\$ 6,761	\$ 4,696
Management transition costs	3,615	5,626	14,590	7,826
Termination and restructuring costs	3,436	3,213	5,441	5,859
	<u>\$ 11,247</u>	<u>\$ 10,859</u>	<u>\$ 26,792</u>	<u>\$ 18,381</u>

Balance at January 1, 2023		\$ 2,222,805
Increase from acquisitions		337
Increase from contributions of redeemable noncontrolling interests		2,820
Balance at December 31, 2023		2,225,962
Increase from acquisitions		35,064
Balance at March 31, 2024		\$ 2,261,026

6. Other Current Assets

Other current assets consisted of the following (in thousands):

	September 30, 2023	December 31, 2022	March 31, 2024	December 31, 2023
	2023	2022	2024	2023
Income taxes receivable	\$ 102,365	\$ 5,767	\$ 38,427	\$ 12,416
Prepaid expenses	38,082	27,052	30,190	36,085
Insurance receivable – current portion	36,579	10,158	23,586	33,579
Other receivables			22,867	22,084
Assets held for sale	30,522	8,347	12,865	11,496
Other receivables	14,288	15,371		
Workers' compensation deposits – current portion	12,000	12,000	12,000	12,000
Inventory	5,475	5,087	5,745	5,300
Other	1,907	2,255	1,632	1,516
Other current assets	\$ 241,218	\$ 86,037	\$ 147,312	\$ 134,476

7. Property and Equipment

Property and equipment consisted of the following (in thousands):

	September 30, 2023	December 31, 2022
	2023	2022
Land	\$ 182,393	\$ 169,137
Building and improvements	1,997,522	1,797,809
Equipment	345,873	292,200
Construction in progress	353,001	349,473
	2,878,789	2,608,619
Less: accumulated depreciation	(733,190)	(656,574)
Property and equipment, net	\$ 2,145,599	\$ 1,952,045

During the nine months ended September 30, 2023, the Company recorded a non-cash property impairment charge of \$2.0 million and a non-cash operating lease right-of-use asset impairment charge of \$2.0 million related to the closure of certain facilities, which is included in loss on impairment in the condensed consolidated statements of operations.

March 31, 2024	December 31, 2023

Land	\$ 195,216	\$ 183,347
Building and improvements	2,088,489	2,064,353
Equipment	383,053	365,826
Construction in progress	506,010	420,430
	3,172,768	3,033,956
Less: accumulated depreciation	(796,709)	(767,346)
Property and equipment, net	\$ 2,376,059	\$ 2,266,610

The Company has recorded assets held for sale within other **current** assets on the **condensed** consolidated balance sheets for closed properties actively marketed of **\$30.5** **12.9** million and **\$8.3** **11.5** million at **September 30, 2023** **March 31, 2024** and **December 31, 2022** **December 31, 2023**, respectively.

8. Other Intangible Assets

Other identifiable intangible assets and related accumulated amortization consisted of the following (in thousands):

	Gross Carrying Amount				Accumulated Amortization							
	Septem ber 30, 2023		Decemb er 31, 2022		Septem ber 30, 2023		Decemb er 31, 2022		March 31, 2024		December 31, 2023	
Intangible assets subject to amortization:												
Non-compete agreements	1,13		(1,13)		(1,13)		(1,13)		\$ 1,131	\$ 1,131	\$ (1,131)	\$ (1,131)
	\$ 1,131	\$ 1	\$ 1)		\$ 1)		\$ 1)					
Intangible assets not subject to amortization:												
Licenses and accreditations	11,65		11,5						11,721	11,681	—	—
	1		12		—		—					
Trade names	43,21		45,9						42,588	42,588	—	—
	0		35		—		—					
Certificates of need	18,95		18,5						19,043	19,009	—	—
	0		94		—		—					
	73,81		76,0									
	1		41		—		—		73,352	73,278	—	—
Total	\$ 74,94	\$ 77,1	(1,13)	(1,13)					\$ 74,483	\$ 74,409	\$ (1,131)	\$ (1,131)
	\$ 2	\$ 72	\$ 1)	\$ 1)								

All of the Company's definite-lived intangible assets are fully amortized. The Company's licenses and accreditations, trade names and certificates of need have indefinite lives and are, therefore, not subject to amortization. During the nine months ended September 30, 2023, the Company recorded a non-cash indefinite-lived intangible asset impairment charge of \$4.7 million related to the closure of certain facilities, which is included in loss on impairment in the condensed consolidated statements of operations.

9. The CARES Act

As part of the Coronavirus Aid, Relief and Economic Security Act (the "CARES Act"), the U.S. government announced it would offer \$100 billion of relief to eligible healthcare providers. On April 24, 2020, then President Trump signed into law the Paycheck Protection Program and Health Care Enhancement Act (the "PPP Act"). Among other things, the PPP Act allocated \$75 billion to eligible healthcare providers to help offset losses and expenses related to the novel coronavirus known as COVID-19 ("COVID-19"). The \$75 billion allocated under the PPP Act was in addition to the \$100 billion allocated to healthcare providers for the same purposes in the CARES Act and has been disbursed to providers under terms and conditions similar to the CARES Act funds. The Company accounts for government grants by analogizing to the grant model in accordance with International Accounting Standard ("IAS") 20, *Accounting for Government Grants and Disclosure of Government Assistance*, and as such, has recognized income from grants in line with the recognition of expenses or the loss of

revenues for which the grants are intended to compensate. The Company recognizes grants once both of the following conditions are met: (i) the Company is able to comply with the relevant terms and conditions of the grant and (ii) the grant will be received.

During 2020, the The Company has participated in certain relief programs offered through the CARES Act, including receipt of approximately \$34.9 million funds relating to the Public Health and Social Services Emergency Fund (the "PHSSE ("PHSSE Fund"), also known as the Provider Relief Fund. During the fourth quarter of 2020, the Company recorded approximately \$32.8 million of income from provider relief fund related to PHSSE Fund amounts received in 2020.

In 2021, the Company received \$24.2 million of additional funds from the PHSSE Fund. During the fourth quarter of 2021, the Company recorded \$17.9 million of income from provider relief fund related to the PHSSE Fund amounts received. During the year ended December 31, 2022, the Company received \$7.7 million of additional funds from the PHSSE Fund, and \$14.2 million from the American Rescue Plan ("ARP") Rural Payments for Hospitals. During the year ended December 31, 2022 December 31, 2023, the Company recorded \$21.5 million of income from provider relief fund

related to PHSSE Fund and ARP funds received. During the third quarter of 2023, the Company recorded \$4.4 million of income from provider relief fund related to ARP funds received. The remaining unrecognized funds of \$4.5 million received and \$9.0 million are included in other accrued liabilities on the condensed consolidated balance sheets at September 30, 2023 and December 31, 2022, respectively. The Company continues to evaluate its compliance with the terms and conditions to, and the financial impact of, the additional funds received, including potential repayment of repaid the remaining balance. balance of ARP funds to eliminate the liability.

Healthcare providers were required to sign an attestation confirming receipt of the PHSSE Fund amounts and agree to the terms and conditions of payment. Under the terms and conditions for receipt of the payment, the Company was allowed to use the funds to cover lost revenues and healthcare costs related to the novel coronavirus known as COVID-19 ("COVID-19"), and the Company was required to properly and fully document the use of these funds to the U.S. Department of Health and Human Services. The reporting of these funds is subject to future audit for compliance with the terms and conditions. The Company recognized PHSSE Fund amounts to the extent it had qualifying COVID-19 expenses or lost revenues as permitted under the terms and conditions.

10. Commitments and Contingencies

During 2020, the Company applied for Professional and received approximately \$45.2 million of payments from the CMS Accelerated and Advance Payment Program. Of the \$45.2 million of advance payments received in 2020, the Company repaid approximately \$25.1 million of advance payments during 2021 and made additional repayments of approximately \$20.1 million during the year ended December 31, 2022.

In addition, the Company received a 2% increase in facilities' Medicare reimbursement rate as a result of the temporary suspension of Medicare sequestration from May 1, 2020 to March 31, 2022, which was reduced to 1% on April 1, 2022 and was eliminated effective July 1, 2022.

The CARES Act also provided for certain federal income and other tax changes. The Company received a cash benefit of approximately \$39.3 million for 2020 relating to the delay of payment of the employer portion of Social Security payroll taxes. The Company repaid half of the \$39.3 million of payroll tax deferrals during the third quarter of 2021 and repaid the remaining portion in the third quarter of 2022 to eliminate the liability.

These regulatory changes were temporary and expired at the end of the COVID-19 public health emergency on May 11, 2023. General Liability

The Company is continuing subject to evaluate medical malpractice and other lawsuits due to the nature of the services the Company provides. A portion of the Company's professional liability risks are insured through a wholly-owned insurance subsidiary providing coverage for up to \$5.0 million per claim and \$10.0 million for certain other claims through August 31, 2023 and \$7.0 million and \$10.0 million for certain other claims thereafter. The Company has obtained reinsurance coverage from a third-party to cover claims in excess of those limits. The reinsurance policy has a coverage limit of \$75.0 million or \$70.0 million in the aggregate for certain other claims through August 31, 2023 and \$78.0 million or \$75.0 million in the aggregate for certain other claims thereafter. The Company's reinsurance receivables are recognized consistent with the related liabilities and include known claims and any incurred but not reported claims that are covered by current insurance policies in place.

Legal Proceedings

The Company is, from time to time, subject to various claims, lawsuits, governmental investigations and regulatory actions, including claims for damages for personal injuries, medical malpractice, overpayments, breach of contract, securities law violations, tort and employment related claims. In these actions, plaintiffs request a variety of damages, including, in some instances, punitive and other types of damages that may not be covered by insurance. In addition, healthcare companies are subject to numerous investigations by various governmental agencies. Certain of the Company's individual facilities have received, and from time to time, other facilities may receive, subpoenas, civil investigative demands, audit requests and other inquiries from, and may be subject to investigation by, federal and state agencies. These investigations can result in repayment obligations and violations of the federal False Claims Act can result in substantial monetary penalties and fines, the imposition of a corporate integrity agreement and exclusion from participation in governmental health programs. In addition, the False Claims Act permits private parties to bring *qui tam*, or "whistleblower," suits against companies that submit false claims for payments to, or improperly retain overpayments from, the government. Some states have adopted similar state whistleblower and false claims provisions.

Desert Hills

From October 2018 to August 2020, the Company, its subsidiary Youth and Family Centered Services of New Mexico ("Desert Hills"), and FamilyWorks, a not-for-profit treatment foster care program to which Desert Hills provided management services, including day-to-day administration of the program, via a management services agreement, were among a number of defendants named in five lawsuits (collectively, the "Desert Hills Litigation") filed in New Mexico State District Court (the "District Court"). These lawsuits each related to abuse by a foster parent, Clarence Garcia, that occurred in foster homes where FamilyWorks had placed children. In 2021, the Company finalized out-of-court settlements for two of the five cases for amounts covered under the Company's professional liability insurance: *Dorsey, as Guardian ad Litem of M.R. v. Clarence Garcia, et al.*, and *Higgins, as Guardian ad Litem of J.H. v. Clarence Garcia, et al.* While the plaintiffs in those two cases had claims pending against FamilyWorks, and FamilyWorks had raised claims or potential claims against the Company, in February 2024, the parties in each of those cases jointly notified the District Court that proposed settlements of all claims had been reached and that, pending the District Court's approval of such proposed settlements, the proposed settlements would also resolve all claims between FamilyWorks and the Company. The Company currently reasonably expects the proposed settlements for the two cases to be approved by the District Court in the coming months.

On July 7, 2023, in connection with one of the lawsuits in the Desert Hills Litigation styled *Inman v. Garcia, et al.*, Case No. D-117-CV-2019-00136 (the "Inman Litigation"), a jury awarded the plaintiff compensatory damages of \$80.0 million and punitive damages of \$405.0 million. This award far exceeded the Company's reasonable expectation based on the previously resolved complaints and far exceeded any precedent for comparable cases.

On October 30, 2023, the Company and Desert Hills entered into settlement agreements in connection with the Inman Litigation, as well as two other related cases – *Rael v. Garcia, et al, Case No. D-117-CV-2019-00135* and *Endicott-Quinones v. Garcia, et al, Case No. D-117-CV-2019-00137* (together with the Inman Litigation, the “Cases”).

The settlement agreements for the Cases were approved by the District Court in December 2023 and fully resolve each of the Cases with no admission of liability or wrongdoing by either the Company or Desert Hills. On January 19, 2024, pursuant to the terms of the settlement agreements, the Company paid an aggregate amount of \$400.0 million in exchange for the release and conditions discharge of all claims arising from, relating to, concerning or with respect to all harm, injuries or damages asserted or that may be asserted in the future.

On January 30, 2024, a sixth lawsuit styled *CNRAG, Inc. as Legal Guardian of A.C. v. Garcia et al., No. D-117-CV-2024-00045* was filed in the District Court alleging similar claims as the previous five lawsuits in the Desert Hills Litigation. The ward in this sixth lawsuit was referenced in prior criminal charges against Garcia five years ago; however, prior to this lawsuit, neither the ward nor guardian made contact with the Company about a possible claim. The Company determined that a lawsuit from this plaintiff was unlikely because no claims had ever been asserted and the statute of limitations had expired. Plaintiff’s allegations assert certain claims, which, if true, may toll the statute of limitations. At this time, the Company is not able to quantify the ultimate liability, if any, in connection with this sixth lawsuit. No additional victims are referenced in the prior criminal charges against Garcia.

Securities Litigation

On April 1, 2019, a consolidated complaint was filed against the Company and certain former and current officers in the lawsuit styled *St. Clair County Employees’ Retirement System v. Acadia Healthcare Company, Inc., et al., Case No. 3:19-cv-00988*, which is pending in the United States District Court for the Middle District of Tennessee. The complaint is brought on behalf of a class consisting of all persons (other than defendants) who purchased securities of the Company between April 30, 2014 and November 15, 2018, and alleges that defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder. On September 30, 2022, the court entered an order certifying a class consisting of all persons who purchased or otherwise acquired the common stock of the Company between April 30, 2014 and November 15, 2018.

Derivative Actions

On February 21, 2019, a purported stockholder filed a related derivative action on behalf of the Company against certain former and current officers and directors in the lawsuit styled *Davydov v. Jacobs, et al., Case No. 3:19-cv-00167*, which is pending in the United States District Court for the Middle District of Tennessee. The complaint alleges claims for violations of Section 10(b) and 14(a) of the Exchange Act, breach of fiduciary duty, waste of corporate assets, and unjust enrichment. On May 23, 2019, a purported stockholder filed a second related derivative action on behalf of the Company against certain former and current officers and directors in the lawsuit styled *Beard v. Jacobs, et al., Case No. 3:19-cv-0441*, which is pending in the United States District Court for the Middle District of Tennessee. The complaint alleges claims for violations of Sections 10(b), 14(a), and 21D of the Exchange Act, breach of fiduciary duty, waste of corporate assets, unjust enrichment, and insider selling. On June 11, 2019, the Davydov and Beard actions were consolidated. On February 22, 2021, the court entered an order staying the case. On October 23, 2020, a purported stockholder filed a third related

derivative action on behalf of the Company against former and current officers and directors in the lawsuit styled *Pfenning v. Jacobs, et al.*, Case No. 2020-0915-NAC, which is pending in the Court of Chancery of the State of Delaware. The complaint alleges claims for breach of fiduciary duty. On February 17, 2021, the court entered an order staying the case. On February 24, 2021, a purported stockholder filed a fourth derivative action on behalf of the Company against former and current officers and directors in the lawsuit styled *Solak v. Jacobs, et al.*, Case No. 2021-0163-NAC, which is pending in the Court of Chancery of the State of Delaware. The complaint alleges claims for breach of fiduciary duty, unjust enrichment, waste of corporate assets, and insider selling.

Government Investigation

In the fall of 2017, the Office of Inspector General (the "OIG") issued subpoenas to three of the Company's facilities requesting certain documents from January 2013 to the date of the subpoenas. The U.S. Attorney's Office for the Middle District of Florida issued a civil investigative demand to one of the Company's facilities in December 2017 requesting certain documents from November 2012 to the date of the demand. In April 2019, the OIG issued subpoenas relating to six additional facilities requesting certain documents and information from January 2013 to the date of the subpoenas. In June 2023, the State of Nevada issued a subpoena relating to one of the same facilities as part of the same investigation. The government's investigation of each of these facilities is focused on claims not eligible for payment because of alleged violations of certain regulatory requirements relating to, among other things, medical necessity, admission eligibility, discharge decisions, length of stay and patient care issues. The Company has reached a tentative agreement to resolve the matter and the anticipated financial impact of funds received under such resolution is \$19.9 million and has been recorded within other accrued liabilities on the CARES Act condensed consolidated balance sheets at March 31, 2024 and other government relief programs December 31, 2023, respectively.

10

10.11. Other Accrued Liabilities

Other accrued liabilities consisted of the following (in thousands):

	September 30,	December 31,	March 31,	December 31,
	2023	2022	2024	2023
Accrued legal settlements	\$ 394,181	\$ —		
Accrued expenses			\$ 63,582	\$ 80,733
Accrued interest			18,446	18,046
Insurance liability – current portion	38,690	12,128	12,486	12,486

Accrued expenses	35,000	26,699		
Accrued property taxes			6,381	7,097
Cost report payable	20,527	13,738	4,363	9,265
Accrued interest	17,400	17,596		
Accrued property taxes	11,684	9,009		
Government relief funds	4,534	8,975		
Contract liabilities	2,585	6,653	2,154	2,165
Finance lease liabilities	990	990	990	990
Income taxes payable	696	1,338		
Accrued Desert Hills settlement			—	393,696
Other	13,660	13,466	11,509	7,783
Other accrued liabilities	\$ 539,947	\$ 110,592	\$ 119,911	\$ 532,261

10

11. 12. Long-Term Debt Commitments and Contingencies

Long-term debt consisted of the following (in thousands):

	September 30, 2023	December 31, 2022
Credit Facility:		
Term Loan A	\$ 382,500	\$ 398,438
Revolving Line of Credit	80,000	75,000
5.500% Senior Notes due 2028	450,000	450,000
5.000% Senior Notes due 2029	475,000	475,000
Less: unamortized debt issuance costs, discount and premium	(10,983)	(12,647)
	<u>1,376,517</u>	<u>1,385,791</u>
Less: current portion	(26,563)	(21,250)
Long-term debt	<u>\$ 1,349,954</u>	<u>\$ 1,364,541</u>

Credit Facility Professional and General Liability

The Company entered into is subject to medical malpractice and other lawsuits due to the nature of the services the Company provides. A portion of the Company's professional liability risks are insured through a credit agreement establishing a new senior credit facility (the "Credit Facility") on March 17, 2021. The Credit Facility provides wholly-owned insurance subsidiary providing coverage for a \$600.0 million senior secured revolving credit facility (the "Revolving Facility")

and a \$425.0 million senior secured term loan facility (the "Term Loan Facility" and, together with the Revolving Facility, the "Senior Facilities"), with each maturing on March 17, 2026. The Revolving Facility further provides for (i) up to \$20.0 million which may be utilized for the issuance of letters of credit per claim and (ii) the availability of a swingline facility under which the Company may borrow up to \$20.0 million.

On March 30, 2023, the Company entered into the First Amendment to the Credit Facility (the "First Amendment"). The First Amendment replaced LIBOR with the Secured Overnight Financing Rate as determined for a term of, at the Company's option, one, three or six months, plus an adjustment of 0.10% ("Adjusted Term SOFR"). Borrowings under the Credit Facility bear interest at a rate equal to, at the Company's option, either (a) a base rate determined by reference to the highest of (i) the federal funds rate plus 0.50%, (ii) the prime rate of Bank of America or (iii) Adjusted Term SOFR for a one month interest period or (b) Adjusted Term SOFR, in each case plus an applicable margin that varies according to the total leverage ratio of the Company from 0.375% to 1.250% in the case of base rate loans and from 1.375% to 2.250% in the case of Adjusted Term SOFR loans. In addition, an unused fee that varies according to the total leverage ratio of the Company from 0.200% to 0.350% is payable quarterly in arrears based on the average daily undrawn portion of the commitments in respect of the Revolving Facility. There is no significant impact on the Company's consolidated financial statements as a result of the First Amendment.

During the nine months ended September 30, 2023, the Company borrowed \$40.0 million on the Revolving Facility and repaid \$35.0 million of the balance outstanding. The Company had \$516.5 million of availability under the Revolving Facility and had standby letters of credit outstanding of \$3.5 million related to security for the payment of claims required by its workers' compensation insurance program at September 30, 2023.

The Credit Facility requires quarterly term loan principal repayments for the Term Loan Facility of approximately \$5.3 million for December 31, 2023 to March 31, 2024, approximately certain other claims through August 31, 2023 and \$8.0 million and \$10.0 million for June 30, 2024 certain other claims thereafter. The Company has obtained reinsurance coverage from a third-party to March 31, 2025, and approximately cover claims in excess of those limits. The reinsurance policy has a coverage limit of \$10.6 million or \$70.0 million in the aggregate for June 30, 2025 to December 31, 2025, certain other claims through August 31, 2023 and \$78.0 million or \$75.0 million in the aggregate for certain other claims thereafter. The Company's reinsurance receivables are recognized consistent with the remaining principal balance of the Term Loan Facility due on the maturity date of related liabilities and include known claims and any incurred but not reported claims that are covered by current insurance policies in place.

March 17, 2026. Legal Proceedings

The Company has the ability is, from time to increase the amount time, subject to various claims, lawsuits, governmental investigations and regulatory actions, including claims for damages for personal injuries, medical malpractice, overpayments, breach of contract, securities law violations, tort and employment related claims. In these actions, plaintiffs request a variety of damages, including, in some instances, punitive and other types of damages that may not be covered by insurance. In addition, healthcare companies are subject to numerous investigations by various governmental agencies. Certain of the Senior Facilities, Company's individual facilities have received, and from time to time, other facilities may receive, subpoenas, civil investigative demands, audit requests and other inquiries from, and may be subject to investigation by, federal and state agencies. These investigations can result in repayment obligations and

violations of the federal False Claims Act can result in substantial monetary penalties and fines, the imposition of a corporate integrity agreement and exclusion from participation in governmental health programs. In addition, the False Claims Act permits private parties to bring qui tam, or "whistleblower," suits against companies that submit false claims for payments to, or improperly retain overpayments from, the government. Some states have adopted similar state whistleblower and false claims provisions.

Desert Hills

From October 2018 to August 2020, the Company, its subsidiary Youth and Family Centered Services of New Mexico ("Desert Hills"), and FamilyWorks, a not-for-profit treatment foster care program to which may take Desert Hills provided management services, including day-to-day administration of the form program, via a management services agreement, were among a number of increases to the Revolving Facility or the Term Loan Facility or the issuance of one or more incremental term loan facilities defendants named in five lawsuits (collectively, the "Incremental Facilities" "Desert Hills Litigation"), upon obtaining additional commitments from new filed in New Mexico State District Court (the "District Court"). These lawsuits each related to abuse by a foster parent, Clarence Garcia, that occurred in foster homes where FamilyWorks had placed children. In 2021, the Company finalized out-of-court settlements for two of the five cases for amounts covered under the Company's professional liability insurance: *Dorsey, as Guardian ad Litem of M.R. v. Clarence Garcia, et al., and Higgins, as Guardian ad Litem of J.H. v. Clarence Garcia, et al.* While the plaintiffs in those two cases had claims pending against FamilyWorks, and FamilyWorks had raised claims or existing lenders potential claims against the Company, in February 2024, the parties in each of those cases jointly notified the District Court that proposed settlements of all claims had been reached and that, pending the District Court's approval of such proposed settlements, the proposed settlements would also resolve all claims between FamilyWorks and the satisfaction Company. The Company currently reasonably expects the proposed settlements for the two cases to be approved by the District Court in the coming months.

On July 7, 2023, in connection with one of customary conditions precedent for such Incremental Facilities. Such Incremental Facilities may not exceed the sum of (i) lawsuits in the greater Desert Hills Litigation styled *Inman v. Garcia, et al, Case No. D-117-CV-2019-00136* (the "Inman Litigation"), a jury awarded the plaintiff compensatory damages of \$480.0 80.0 million and an amount equal to punitive damages of \$100% of the Consolidated EBITDA (as defined in the Credit Facility) of the Company and (ii) additional amounts that would not cause the Consolidated Senior Secured Net Leverage Ratio (as defined in the Credit Facility) to exceed 3.5 405.0 to 1.0.

Subject to certain exceptions, substantially all of million. This award far exceeded the Company's existing reasonable expectation based on the previously resolved complaints and subsequently acquired or organized direct or indirect wholly-owned subsidiaries are required to guarantee the repayment of the Company's obligations under the Credit Facility. The Company and such guarantor subsidiaries have granted a security interest on substantially all personal property assets as collateral far exceeded any precedent for the obligations under the Credit Facility. comparable cases.

On October 30, 2023, the Company and Desert Hills entered into settlement agreements in connection with the Inman Litigation, as well as two other related cases – *Rael v. Garcia, et al, Case No. D-117-CV-2019-00135* and *Endicott-Quinones v. Garcia, et al, Case No. D-117-CV-2019-00137* (together with the Inman Litigation, the “Cases”).

The Credit Facility contains customary representations settlement agreements for the Cases were approved by the District Court in December 2023 and affirmative fully resolve each of the Cases with no admission of liability or wrongdoing by either the Company or Desert Hills. On January 19, 2024, pursuant to the terms of the settlement agreements, the Company paid an aggregate amount of \$400.0 million in exchange for the release and negative covenants, including discharge of all claims arising from, relating to, concerning or with respect to all harm, injuries or damages asserted or that may be asserted in the future.

On January 30, 2024, a sixth lawsuit styled *CNRAG, Inc. as Legal Guardian of A.C. v. Garcia et al., No. D-117-CV-2024-00045* was filed in the District Court alleging similar claims as the previous five lawsuits in the Desert Hills Litigation. The ward in this sixth lawsuit was referenced in prior criminal charges against Garcia five years ago; however, prior to this lawsuit, neither the ward nor guardian made contact with the Company about a possible claim. The Company determined that a lawsuit from this plaintiff was unlikely because no claims had ever been asserted and the statute of limitations had expired. Plaintiff's allegations assert certain claims, which, if true, may toll the statute of limitations. At this time, the Company is not able to quantify the ultimate liability, if any, in connection with this sixth lawsuit. No additional victims are referenced in the prior criminal charges against Garcia.

Securities Litigation

On April 1, 2019, a consolidated complaint was filed against the Company and certain former and current officers in the lawsuit styled *St. Clair County Employees' Retirement System v. Acadia Healthcare Company, Inc., et al., Case No. 3:19-cv-00988*, which is pending in the United States District Court for the Middle District of Tennessee. The complaint is brought on behalf of a class consisting of all persons (other than defendants) who purchased securities of the Company between April 30, 2014 and November 15, 2018, and alleges that defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder. On September 30, 2022, the court entered an order certifying a class consisting of all persons who purchased or otherwise acquired the common stock of the Company between April 30, 2014 and November 15, 2018.

Derivative Actions

On February 21, 2019, a purported stockholder filed a related derivative action on behalf of the Company against certain former and current officers and directors in the lawsuit styled *Davydov v. Jacobs, et al., Case No. 3:19-cv-00167*, which is pending in the United States District Court for the Middle District of Tennessee. The complaint alleges claims for violations of Section 10(b) and 14(a) of the Exchange Act, breach of fiduciary duty, waste of corporate assets, and unjust enrichment. On May 23, 2019, a purported stockholder filed a second related derivative action on behalf of the Company

against certain former and current officers and directors in the lawsuit styled *Beard v. Jacobs, et al.*, Case No. 3:19-cv-0441, which is pending the United States District Court for the Middle District of Tennessee. The complaint alleges claims for violations of Sections 10(b), 14(a), and 21D of the Exchange Act, breach of fiduciary duty, waste of corporate assets, unjust enrichment, and insider selling. On June 11, 2019, the Davydov and Beard actions were consolidated. On February 22, 2021, the court entered an order staying the case. On October 23, 2020, a purported stockholder filed a third related derivative action on behalf of the Company against former and current officers and directors in the lawsuit styled *Pfenning v. Jacobs, et al.*, Case No. 2020-0915-NAC, which is pending in the Court of Chancery of the State of Delaware. The complaint alleges claims for breach of fiduciary duty. On February 17, 2021, the court entered an order staying the case. On February 24, 2021, a purported stockholder filed a fourth derivative action on behalf of the Company against former and current officers and directors in the lawsuit styled *Solak v. Jacobs, et al.*, Case No. 2021-0163-NAC, which is pending in the Court of Chancery of the State of Delaware. The complaint alleges claims for breach of fiduciary duty, unjust enrichment, waste of corporate assets, and insider selling.

Government Investigation

In the fall of 2017, the Office of Inspector General (the "OIG") issued subpoenas to three of the Company's and its subsidiaries' ability facilities requesting certain documents from January 2013 to incur additional debt, grant or permit additional liens, make investments and acquisitions, merge or consolidate with others, dispose of assets, pay dividends and distributions, pay junior indebtedness and enter into affiliate transactions, in each case, subject to customary exceptions. In addition, the Credit Facility contains financial covenants requiring the Company on a consolidated basis to maintain, as date of the last day subpoenas. The U.S. Attorney's Office for the Middle District of any consecutive four fiscal quarter period, Florida issued a consolidated total net leverage ratio civil investigative demand to one of the Company's facilities in December 2017 requesting certain documents from November 2012 to the date of the demand. In April 2019, the OIG issued subpoenas relating to six additional facilities requesting certain documents and information from January 2013 to the date of the subpoenas. In June 2023, the State of Nevada issued a subpoena relating to one of the same facilities as part of the same investigation. The government's investigation of each of these facilities is focused on claims not more than 5.0 eligible for payment because of alleged violations of certain regulatory requirements relating to, 1.0 and an interest coverage ratio of at least 3.0 to 1.0. The Credit Facility also includes events of default customary for facilities of this type and upon the occurrence of any such event of default, among other things, all outstanding loans under medical necessity, admission eligibility, discharge decisions, length of stay and patient care issues. The Company has reached a tentative agreement to resolve the Senior Facilities may be accelerated, matter and the lenders' commitments may be terminated, and/or the lenders may exercise collateral remedies. At September 30, 2023, the Company was in compliance with all anticipated financial covenants.

Senior Notes

5.500% Senior Notes due 2028

On June 24, 2020, the Company issued impact of such resolution is \$450.0 19.9 million of 5.500% Senior Notes due 2028 (the "5.500% Senior Notes"). The 5.500% Senior Notes mature and has been recorded within other accrued liabilities on the condensed consolidated balance sheets at March 31, 2024 and December 31, 2023, respectively.

and bear interest at a rate of 5.500% per annum, payable semi-annually in arrears on January 1 and July 1 of each year.

5.000% Senior Notes due 2029

On October 14, 2020, the Company issued \$475.0 million of 5.000% Senior Notes due 2029 (the “5.000% Senior Notes”). The 5.000% Senior Notes mature on April 15, 2029, and bear interest at a rate of 5.000% per annum, payable semi-annually in arrears on April 15 and October 15 of each year.

The indentures governing the 5.500% Senior Notes and the 5.000% Senior Notes (together, the “Senior Notes”) contain covenants that, among other things, limit the Company’s ability and the ability of its restricted subsidiaries to: (i) pay dividends, redeem stock or make other distributions or investments; (ii) incur additional debt or issue certain preferred stock; (iii) transfer or sell assets; (iv) engage in certain transactions with affiliates; (v) create restrictions on dividends or other payments by the restricted subsidiaries; (vi) merge, consolidate or sell substantially all of the Company’s assets; and (vii) create liens on assets.

The Senior Notes issued by the Company are guaranteed by each of the Company’s subsidiaries that guarantee the Company’s obligations under the Credit Facility. The guarantees are full and unconditional and joint and several.

The Company may redeem the Senior Notes at its option, in whole or part, at the dates and in the amounts set forth in the applicable indentures.

11. Other Accrued Liabilities

Other accrued liabilities consisted of the following (in thousands):

	March 31,	December 31,	
	2024	2023	
Accrued expenses	\$ 63,582	\$ 80,733	
Accrued interest	18,446	18,046	
Insurance liability – current portion	12,486	12,486	
Accrued property taxes	6,381	7,097	
Cost report payable	4,363	9,265	
Contract liabilities	2,154	2,165	
Finance lease liabilities	990	990	
Accrued Desert Hills settlement	—	393,696	
Other	11,509	7,783	

Other accrued liabilities	\$ 119,911	\$ 532,261
---------------------------	------------	------------

12. Commitments and Contingencies

Professional and General Liability

The Company is subject to medical malpractice and other lawsuits due to the nature of the services the Company provides. A portion of the Company's professional liability risks are insured through a wholly-owned insurance subsidiary providing coverage for up to \$5.0 million per claim and \$10.0 million for certain other claims through August 31, 2023, and \$7.0 million and \$10.0 million for certain other claims thereafter. The Company has obtained reinsurance coverage from a third party third-party to cover claims in excess of those retention limits. The reinsurance policy has a coverage limit of \$75.0 million or \$70.0 million in the aggregate for certain other claims through August 31, 2023, and \$78.0 million or \$75.0 million in the aggregate for certain other claims thereafter. The Company's reinsurance receivables are recognized consistent with the related liabilities and include known claims and any incurred but not reported claims that are covered by current insurance policies in place.

Legal Proceedings

The Company is, from time to time, subject to various claims, lawsuits, governmental investigations and regulatory actions, including claims for damages for personal injuries, medical malpractice, overpayments, breach of contract, securities law violations, tort and employment related claims. In these actions, plaintiffs request a variety of damages, including, in some instances, punitive and other types of damages that may not be covered by insurance. In addition, healthcare companies are subject to numerous investigations by various governmental agencies. Certain of the Company's individual facilities have received, and from time to time, the Company's other facilities may receive, subpoenas, civil investigative demands, audit requests and other inquiries from, and may be subject to investigation by, federal and state agencies. These investigations can result in repayment obligations and violations of the federal False Claims Act can result in substantial monetary penalties and fines, the imposition of a corporate integrity agreement and exclusion from participation in governmental health programs. In addition, the False Claims Act permits private parties to bring qui tam, or "whistleblower," suits against companies that submit false claims for payments to, or improperly retain overpayments from, the government. Some states have adopted similar state whistleblower and false claims provisions.

12

Desert Hills

From October 2018 to August 2020, the Company, its subsidiary Youth and Family Centered Services of New Mexico ("Desert Hills"), and FamilyWorks, a not-for-profit treatment foster care program to which Desert Hills provided management services, including day-to-day administration of the program, via a management services agreement, were among a number of defendants named in five lawsuits (collectively, the "Desert Hills Litigation") filed in New Mexico State District Court (the "District Court"). These lawsuits each related to abuse by a foster parent, Clarence Garcia, that occurred in foster homes where FamilyWorks had placed children. In 2021, the Company finalized out-of-court settlements for two of the five cases for amounts covered under the Company's professional liability insurance. insurance: Dorsey, as Guardian

ad Litem of M.R. v. Clarence Garcia, et al ., and Higgins, as Guardian ad Litem of J.H. v. Clarence Garcia, et al. While the plaintiffs in those two cases had claims pending against FamilyWorks, and FamilyWorks had raised claims or potential claims against the Company, in February 2024, the parties in each of those cases jointly notified the District Court that proposed settlements of all claims had been reached and that, pending the District Court's approval of such proposed settlements, the proposed settlements would also resolve all claims between FamilyWorks and the Company. The Company currently reasonably expects the proposed settlements for the two cases to be approved by the District Court in the coming months.

On July 7, 2023, in connection with one of the lawsuits in the Desert Hills Litigation styled *Inman v. Garcia, et al*, Case No. D-117-CV-2019-00136 (the "Inman Litigation"), a jury awarded the plaintiff compensatory damages of \$80.0 million and punitive damages of \$405.0 million. This award far exceeded the Company's reasonable expectation based on the previously resolved complaints and far exceeded any precedent for comparable cases. The parties made substantial progress during mediation proceedings on October 6, 2023 and October 7, 2023 in an effort to reach settlement agreements to resolve the Inman Litigation as well as the two other related cases –

Rael v. Garcia, et al, Case No. D-117-CV-2019-00135 9

and *Endicott-Quinones v. Garcia, et al, Case No. D-117-CV-2019-00137* (together with the Inman Litigation, the "Cases"). On October 11, 2023, the Company and Desert Hills, in connection with the Inman Litigation, filed an unopposed motion to stay the District Court's requirement of posting a bond and execution of its judgment on the Company, Desert Hills or Family Works, in order to allow for settlement discussions and efforts to finalize a written agreement regarding the Cases to continue unimpeded. The motion was granted by the District Court on October 16, 2023.

On October 30, 2023, the Company and Desert Hills entered into settlement agreements in connection with the Inman Litigation, as well as two other related cases – *Rael v. Garcia, et al, Case No. D-117-CV-2019-00135* and *Endicott-Quinones v. Garcia, et al, Case No. D-117-CV-2019-00137* (together with the Inman Litigation, the "Cases").

The settlement agreements for the Cases were approved by the District Court in December 2023 and fully resolve each of the Cases. Under Cases with no admission of liability or wrongdoing by either the Company or Desert Hills. On January 19, 2024, pursuant to the terms of the settlement agreements, the Company will pay paid an aggregate amount of \$400.0 million in exchange for the release and discharge of all claims arising from, relating to, concerning or with respect to all harm, injuries or damages asserted or that may be asserted in the future.

On January 30, 2024, a sixth lawsuit styled *CNRAG, Inc. as Legal Guardian of A.C. v. Garcia et al., No. D-117-CV-2024-00045* was filed in the District Court alleging similar claims as the previous five lawsuits in the Desert Hills Litigation. The settlement agreements fully resolve each of ward in this sixth lawsuit was referenced in prior criminal charges against

Garcia five years ago; however, prior to this lawsuit, neither the Cases and include no admission of liability or wrongdoing by either ward nor guardian made contact with the Company or Desert Hills.

The settlement agreements are subject to approval by the District Court. about a possible claim. The Company currently intends to pay determined that a lawsuit from this plaintiff was unlikely because no claims had ever been asserted and the funds associated with statute of limitations had expired. Plaintiff's allegations assert certain claims, which, if true, may toll the settlement agreements from a combination statute of insurance, cash on hand and existing credit lines. The settlement amounts must be paid within 30 days from the District Court's approval of the settlement agreements. In respect of the Cases, limitations. At this time, the Company has recorded a legal settlements is not able to quantify the ultimate liability, of \$394.2 million, which is inclusive of associated legal fees and net of reinsurance receivables, within other accrued liabilities and other current assets, respectively, on if any, in connection with this sixth lawsuit. No additional victims are referenced in the condensed consolidated balance sheet at September 30, 2023. prior criminal charges against Garcia.

Securities Litigation

On April 1, 2019, a consolidated complaint was filed against the Company and certain former and current officers in the lawsuit styled *St. Clair County Employees' Retirement System v. Acadia Healthcare Company, Inc., et al.*, Case No. 3:19-cv-00988, which is pending in the United States District Court for the Middle District of Tennessee. The complaint is brought on behalf of a class consisting of all persons (other than defendants) who purchased securities of the Company between April 30, 2014 and November 15, 2018, and alleges that defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder. On September 30, 2022, the court entered an order certifying a class consisting of all persons who purchased or otherwise acquired the common stock of the Company between April 30, 2014 and November 15, 2018. At this time, the Company is not able to quantify any potential liability in connection with this litigation because the case is in its early stages.

Derivative Actions

On February 21, 2019, a purported stockholder filed a related derivative action on behalf of the Company against certain former and current officers and directors in the lawsuit styled *Davydov v. Jacobs, et al.*, Case No. 3:19-cv-00167, which is pending in the United States District Court for the Middle District of Tennessee. The complaint alleges claims for violations of Section 10(b) and 14(a) of the Exchange Act, breach of fiduciary duty, waste of corporate assets, and unjust enrichment. On May 23, 2019, a purported stockholder filed a second related derivative action on behalf of the Company against certain former and current officers and directors in the lawsuit styled *Beard v. Jacobs, et al.*, Case No. 3:19-cv-0441, which is pending in the United States District Court for the Middle District of Tennessee. The complaint alleges claims for violations of Sections 10(b), 14(a), and 21D of the Exchange Act, breach of fiduciary duty, waste of corporate assets, unjust enrichment, and insider selling. On June 11, 2019, the *Davydov* and *Beard* actions were consolidated. On February 22, 2021, the court entered an order staying the case. On October 23, 2020, a purported stockholder filed a third related derivative action on behalf of the Company against former and current officers and directors in the lawsuit styled *Pfenning v. Jacobs, et al.*, Case No. 2020-0915-NAC, which is pending in the Court of Chancery of the State of Delaware. The complaint alleges claims for breach of fiduciary duty. On February 17, 2021, the court entered an order staying the case. On February 24, 2021, a purported stockholder filed a fourth derivative action on behalf of the Company against former and current officers and directors in the lawsuit styled *Solak v. Jacobs, et al.*, Case No. 2021-0163-NAC, which is pending in the

Court of Chancery of the State of Delaware. The complaint alleges claims for breach of fiduciary duty, unjust enrichment, waste of corporate assets, and insider

13

selling. At this time, the Company is not able to quantify any potential liability in connection with this litigation because the cases are in their early stages.

Government Investigation

In the fall of 2017, the Office of Inspector General ("OIG" (the "OIG") issued subpoenas to three of the Company's facilities requesting certain documents from January 2013 to the date of the subpoenas. The U.S. Attorney's Office for the Middle District of Florida issued a civil investigative demand to one of the Company's facilities in December 2017 requesting certain documents from November 2012 to the date of the demand. In April 2019, the OIG issued subpoenas relating to six additional facilities requesting certain documents and information from January 2013 to the date of the subpoenas. In June 2023, the State of Nevada issued a subpoena relating to one of the same facilities as part of the same investigation. The government's investigation of each of these facilities is focused on claims not eligible for payment because of alleged violations of certain regulatory requirements relating to, among other things, medical necessity, admission eligibility, discharge decisions, length of stay and patient care issues. The Company has reached a tentative agreement to resolve the matter and the anticipated financial impact of such resolution is cooperating \$19.9 million and has been recorded within other accrued liabilities on the condensed consolidated balance sheets at March 31, 2024 and December 31, 2023, respectively.

10

11. Other Accrued Liabilities

Other accrued liabilities consisted of the following (in thousands):

	March 31,		December 31,	
	2024	2023	2024	2023
Accrued expenses	\$ 63,582	\$ 80,733		
Accrued interest	18,446	18,046		
Insurance liability – current portion	12,486	12,486		
Accrued property taxes	6,381	7,097		
Cost report payable	4,363	9,265		

Contract liabilities	2,154	2,165
Finance lease liabilities	990	990
Accrued Desert Hills settlement	—	393,696
Other	11,509	7,783
Other accrued liabilities	\$ 119,911	\$ 532,261

12. Long-Term Debt

Long-term debt consisted of the following (in thousands):

	March 31, 2024	December 31, 2023
Credit Facility:		
Term Loan A	\$ 716,945	\$ 377,188
Revolving Line of Credit	225,000	80,000
5.500% Senior Notes due 2028	450,000	450,000
5.000% Senior Notes due 2029	475,000	475,000
Less: unamortized debt issuance costs, discount and premium	(11,197)	(10,421)
	1,855,748	1,371,767
Less: current portion	(61,452)	(29,219)
Long-term debt	\$ 1,794,296	\$ 1,342,548

Credit Facility

On March 17, 2021, the Company entered into a credit agreement (as amended the "Credit Facility"), which provides for a \$600.0 million senior secured revolving credit facility (the "Revolving Facility") and a senior secured term loan facility in an initial principal amount of \$425.0 million (as increased by the Incremental Term Loans (as defined below), the "Term Loan Facility"), each maturing on March 17, 2026. The Revolving Facility further provides for a \$20.0 million subfacility for the issuance of letters of credit.

On March 30, 2023, the Company entered into Amendment No. 1 to the Credit Facility (the "First Amendment"), which replaced the London Interbank Offered Rate ("LIBOR"), as the reference rate applicable to borrowings under the Credit Facility with the government's investigation but Secured Overnight Financing Rate as determined for a term of, at the Company's option, one, three or six months, plus an adjustment of 0.10% ("Adjusted Term SOFR"). After giving effect to the First Amendment, borrowings under the Credit Facility bear interest at a rate equal to, at the Company's option, either (i) Adjusted Term SOFR plus a margin ranging from 1.375% to 2.250% or (ii) a base rate plus a margin ranging from 0.375% to 1.250%, in each case, depending on the consolidated total net leverage ratio. In addition, an unused fee that varies according to the consolidated total net leverage ratio of the Company ranging from 0.200% to 0.350% is not able payable quarterly in arrears based on the average daily undrawn portion of the commitments in respect of the Revolving Facility.

On January 18, 2024, the Company entered into Amendment No. 2 to quantify any potential liability the Credit Facility (the "Second Amendment"), which provides for the incurrence of additional senior secured term loans in connection with these investigations. an aggregate principal amount of \$350.0 million (the "Incremental Term Loans"). Such Incremental Term Loans are structured as an increase of the Term Loan Facility. The maturity date, the leverage-based pricing grid, mandatory prepayment events and other terms applicable to the Incremental Term Loans are substantially identical to those applicable to the initial \$425.0 million term loans incurred under the Term Loan Facility. After giving effect to the Incremental Term Loans, the Credit Facility requires quarterly principal repayments for the Term Loan Facility of approximately \$15.4 million for each quarter ending from June 30, 2024 to March 31, 2025 and \$20.5 million for each quarter ending

11

from June 30, 2025 to December 31, 2025. The remaining outstanding principal balance of the Term Loan Facility is due on the maturity date of March 17, 2026.

The Company has the ability to increase the amount of the Credit Facility, which may take the form of increases to the Revolving Facility or the Term Loan Facility or the issuance of one or more incremental term loan facilities (collectively, the "Incremental Facilities"), upon obtaining additional commitments from new or existing lenders and the satisfaction of customary conditions precedent for such Incremental Facilities. Such Incremental Facilities may not exceed the sum of (i) the greater of \$480.0 million and an amount equal to 100% of the consolidated EBITDA of the Company at the time of determination (the "Incremental Fixed Basket") and (ii) additional amounts that would not cause the Company's consolidated senior secured net leverage ratio to exceed 3.5 to 1.0 (the "Incremental Ratio Basket"). The Incremental Term Loans were incurred in reliance on the Incremental Ratio Basket, leaving the full amount of the Incremental Fixed Basket available for any future Incremental Facilities.

Subject to certain exceptions, substantially all of the Company's existing and subsequently acquired or organized direct or indirect wholly-owned U.S. subsidiaries are required to guarantee the repayment of the Company's obligations under the Credit Facility. The Company and such guarantor subsidiaries have granted a security interest in substantially all personal property assets as collateral for the obligations under the Credit Facility.

The Credit Facility contains customary representations and affirmative and negative covenants, including limitations on the Company's and its subsidiaries' ability to incur additional debt, grant or permit additional liens, make investments and acquisitions, merge or consolidate with others, dispose of assets, pay dividends and distributions, pay junior indebtedness and enter into affiliate transactions, in each case, subject to customary exceptions. In addition, the Credit Facility contains financial covenants requiring the Company on a consolidated basis to maintain, as of the last day of any consecutive four fiscal quarter period, a consolidated total net leverage ratio of not more than 4.5 to 1.0 (which may be

increased to 5.0 to 1.0 for a period of up to four consecutive fiscal quarters following the consummation of certain material acquisitions) and an interest coverage ratio of at least 3.0 to 1.0. The Credit Facility also includes events of default customary for facilities of this type and upon the occurrence of such events of default, among other things, all outstanding loans under the Credit Facility may be accelerated, the lenders' commitments terminated, and/or the lenders may exercise collateral remedies. At March 31, 2024, the Company was in compliance with all financial covenants.

During the three months ended March 31, 2024, the Company borrowed \$160.0 million on the Revolving Facility and repaid \$15.0 million of the balance outstanding. During the three months ended March 31, 2023, the Company borrowed \$40.0 million on the Revolving Facility. The Company had \$371.5 million of availability under the Revolving Facility and had standby letters of credit outstanding of \$3.5 million related to security for the payment of claims required by its workers' compensation insurance program at March 31, 2024.

Senior Notes

5.500% Senior Notes due 2028

On June 24, 2020, the Company issued \$450.0 million of 5.500% Senior Notes due 2028 (the "5.500% Senior Notes"). The 5.500% Senior Notes mature on July 1, 2028 and bear interest at a rate of 5.500% per annum, payable semi-annually in arrears on January 1 and July 1 of each year, commencing on January 1, 2021.

5.000% Senior Notes due 2029

On October 14, 2020, the Company issued \$475.0 million of 5.000% Senior Notes due 2029 (the "5.000% Senior Notes"). The 5.000% Senior Notes mature on April 15, 2029 and bear interest at a rate of 5.000% per annum, payable semi-annually in arrears on April 15 and October 15 of each year, commencing on April 15, 2021.

The indentures governing the 5.500% Senior Notes and the 5.000% Senior Notes (together, the "Senior Notes") contain covenants that, among other things, limit the Company's ability and the ability of its restricted subsidiaries to: (i) pay dividends, redeem stock or make other distributions or investments; (ii) incur additional debt or issue certain preferred stock; (iii) transfer or sell assets; (iv) engage in certain transactions with affiliates; (v) create restrictions on dividends or other payments by the restricted subsidiaries; (vi) merge, consolidate or sell substantially all of the Company's assets; and (vii) create liens on assets.

The Senior Notes issued by the Company are guaranteed by each of the Company's subsidiaries that guarantee the Company's obligations under the Credit Facility. The guarantees are full and unconditional and joint and several.

The Company may redeem the Senior Notes at its option, in whole or part, at the dates and amounts set forth in the indentures.

13. Noncontrolling Interests

Noncontrolling interests in the consolidated financial statements represent the portion of equity held by noncontrolling partners in the Company's non-wholly owned subsidiaries. At **September 30, 2023** **March 31, 2024**, the Company operated ten facilities through non-wholly owned subsidiaries. The Company owns between approximately 65% and 87% of the equity interests of these entities, and noncontrolling

partners own the remaining equity interests. The initial value of the noncontrolling interests is based on the fair value of contributions. The Company consolidates the operations of each facility based on its status as primary beneficiary, as further discussed in Note 14 – Variable Interest Entities. The noncontrolling interests are reflected as redeemable noncontrolling interests on the accompanying condensed consolidated balance sheets based on put rights that could require the Company to purchase the noncontrolling interests upon the occurrence of a change in control.

The components of redeemable noncontrolling interests are as follows (in thousands):

Balance at January 1, 2022	\$ 65,388	
Contributions from noncontrolling partners in joint ventures	21,162	
Net income attributable to noncontrolling interests	6,894	
Acquisition of ownership interests from noncontrolling partners	(4,183)	
Distributions to noncontrolling partners in joint ventures	(1,004)	
Balance at December 31, 2022	88,257	
Balance at January 1, 2023	\$ 88,257	
Contributions from noncontrolling partners in joint ventures	8,827	16,530
Net income attributable to noncontrolling interests	3,978	6,006
Distributions to noncontrolling partners in joint ventures	(3,480)	(5,107)
Balance at September 30, 2023	\$ 97,582	
Balance at December 31, 2023		105,686
Contributions from noncontrolling partners in joint ventures		2,280
Net income attributable to noncontrolling interests		2,387
Distributions to noncontrolling partners in joint ventures		(1,020)
Balance at March 31, 2024	\$ 109,333	

14. Variable Interest Entities

For legal entities where the Company has a financial relationship, the Company evaluates whether it has a variable interest and determines if the entity is considered a variable interest entity ("VIE"). If the Company concludes an entity is a VIE and the Company is the primary beneficiary, the entity is consolidated. The primary beneficiary analysis is a qualitative analysis based on power and benefits. A reporting entity has a controlling financial interest in a VIE and must consolidate

the VIE if it has both power and benefits. It must have the power to direct the activities that most significantly impact the VIE's economic performance and the obligation to absorb losses of the VIE that potentially could be significant to the VIE or the right to receive benefits from the VIE that potentially could be significant to the VIE.

At **September 30, 2023** **March 31, 2024**, the Company operated ten facilities through non-wholly owned subsidiaries. The Company owns between approximately 65% and 87% of the equity interests of these entities, and noncontrolling partners own the remaining equity interests. The Company manages each of these facilities, is responsible for the day-to-day operations and, therefore, has the power to direct the activities that most significantly impact the VIE's economic performance and the obligation to absorb losses or receive benefits from the VIE that could potentially be significant to the VIE. These activities include, but are not limited to, behavioral healthcare services, human resource and employment-related decisions, marketing and finance. The terms of the agreements governing each of the Company's VIEs prohibit the Company from using the assets of each VIE to satisfy the obligations of other entities. Consolidated assets at **September 30, 2023** **March 31, 2024** and **December 31, 2022** **December 31, 2023** include total assets of variable interest entities of **\$535.8** **650.1** million and **\$434.2** **597.8** million, respectively, which cannot be used to settle the obligations of other entities. Consolidated liabilities at **March 31, 2024** and **December 31, 2023** include total liabilities of variable interest entities of **\$29.2** million and **\$27.0** million, respectively.

1413

September 30, 2023 and December 31, 2022 include total liabilities of variable interest entities of \$25.5 million and \$24.4 million, respectively.

The consolidated VIEs assets and liabilities in the Company's condensed consolidated balance sheets are shown below (in thousands):

	September		December			
	30, 2023		31, 2022			
Cash and cash equivalents	\$ 50,531	\$ 32,478	\$ 63,571	\$ 55,149		
Accounts receivable, net	28,643	23,789	36,746	34,910		
Other current assets	2,757	2,561	2,739	2,193		

Total current assets	81,931	58,828	103,056	92,252
Property and equipment, net		313,35		
Goodwill	387,159	8	476,150	438,965
Intangible assets, net	42,384	39,564	42,384	42,384
Operating lease right-of-use assets	18,263	16,139	18,313	18,295
	6,034	6,284	10,231	5,948
Total assets	\$ 535,771	\$ 434,173	\$ 650,134	\$ 597,844
Accounts payable	\$ 6,419	\$ 4,650	\$ 8,611	\$ 8,235
Accrued salaries and benefits	6,531	6,866	6,714	9,909
Current portion of operating lease liabilities	263	233	554	273
Other accrued liabilities	6,044	6,179	3,097	2,385
Total current liabilities	19,257	17,928	18,976	20,802
Operating lease liabilities	6,232	6,433	10,208	6,160
Total liabilities	\$ 25,489	\$ 24,361	\$ 29,184	\$ 26,962

15. Equity-Based Compensation

Equity Incentive Plans

The Company issues stock-based awards, including stock options, restricted stock units and restricted performance stock units, to certain officers, employees and non-employee directors under the Acadia Healthcare Company, Inc. Incentive Compensation Plan (the "Equity Incentive Plan"). At **September 30, 2023** **March 31, 2024**, a maximum of 12,700,000 shares of the Company's common stock were authorized for issuance as stock options, restricted stock units and restricted performance stock units or other share-based compensation under the Equity Incentive Plan, of which **2,667,821** **2,253,481** were available for future grant. Stock options may be granted for terms of up to ten years. The Company recognizes expense on all share-based awards on a straight-line basis over the requisite service period of the entire award. Grants to employees generally vest in annual increments of 25% or 33% each year, commencing one year after the date of grant. The exercise prices of stock options are equal to the most recent closing price of the Company's common stock on the most recent trading date prior to the date of grant.

The Company recognized \$8.2 **8.7** million and \$7.2 **7.6** million in equity-based compensation expense for the three months ended **September 30, 2023** **March 31, 2024** and **2022** and \$23.1 million and \$21.7 million for the nine months ended **September 30, 2023** and **2022, 2023**, respectively. Stock compensation expense for the **nine** **three** months ended

September 30, 2023 March 31, 2024 and 2022 2023 is impacted by forfeiture adjustments and restricted performance stock unit adjustments based on actual performance compared to vesting targets. At September 30, 2023 March 31, 2024, there was \$80.9 87.9 million of unrecognized compensation expense related to unvested options, restricted stock units and restricted performance stock units, which is expected to be recognized over the remaining weighted average vesting period of 1.4 1.3 years.

The Company recognized a deferred income tax benefit of \$2.2 2.4 million and \$2.0 2.1 million for the three months ended September 30, 2023 March 31, 2024 and 2022, 2023, respectively, related to equity-based compensation expense. The Company recognized a deferred income tax benefit of \$6.3 million and \$5.9 million for the nine months ended September 30, 2023 and 2022, respectively.

15 14

Stock Options

Stock option activity during 2022 2023 and 2023 2024 was as follows:

	Weighted Average				Weighted Average			
	Number of Options	Weighted Average	Remaining Contractual Term (in years)	Aggregate Intrinsic Value (in thousands)	Number of Options	Weighted Average	Remaining Contractual Term (in years)	Aggregate Value (in thousands)
		Exercise Price	Term (in years)	Value (in thousands)		Exercise Price	Term (in years)	Value (in thousands)
	Options outstanding at January 1, 2022	1,106	6,064	42.09				
				\$ 7				
	Options outstanding at January 1, 2023				979,277	\$ 46.27		
Options granted	334,260	55.73			296,340	78.94		

Options exercised	(285,	40.6				
	577)	6				
			(198,527)		41.29	
Options cancelled	(175,	46.9				
	475)	8				
			(140,545)		55.95	
Options outstanding at	979,	46.2				
December 31, 2022	277	7				
Options outstanding at						
December 31, 2023			936,545		56.21	
Options granted	271,	79.3				
	740	2				
			1,000		84.18	
Options exercised	(161,	40.5				
	507)	0				
			(90,178)		45.49	
Options cancelled	(99,9	56.6				
	90)	8				
			(22,888)		62.76	
Options outstanding at	989,	55.2				
September 30, 2023	520	\$ 4	7.39	\$ 20,815		
Options exercisable at	392,	42.6				
September 30, 2023	795	\$ 9	5.73	\$ 12,705		
Options outstanding at						
March 31, 2024			824,479	\$ 57.24	7.10	\$ 18,435
Options exercisable at						
March 31, 2024			448,934	\$ 47.76	6.02	\$ 14,197

Fair values are estimated using the Black-Scholes option pricing model. The following table summarizes the grant date fair value of options and the assumptions used to develop the fair value estimates for options granted during the nine three months ended September 30, 2023 March 31, 2024 and year ended December 31, 2022 December 31, 2023:

	September	December		
	30, 2023	31, 2022	March 31, 2024	December 31, 2023
Weighted average grant-date fair value of options	\$ 31.11	\$ 20.72	\$ 30.99	\$ 30.99
Risk-free interest rate	4.1 %	2.0 %	4.0 %	4.2 %
Expected volatility	37 %	39 %	34 %	37 %
Expected life (in years)	5.0	5.0	5.0	5.0

The Company's estimate of expected volatility for stock options is based upon the volatility of its stock price over the expected life of the award. The risk-free interest rate is the approximate yield on U.S. Treasury Strips having a life equal to the expected option life on the date of grant. The expected life is an estimate of the number of years an option will be held before it is exercised.

Other Stock-Based Awards

Restricted stock unit activity during 2022 2023 and 2023 2024 was as follows:

	Weighted Average			Weighted Average	
	Number of Shares	Grant-Date Fair Value		Number of Shares	Grant-Date Fair Value
Unvested at January 1, 2022	926,627	\$ 37.84			
Unvested at January 1, 2023				1,045,202	\$ 54.89
Granted	650,396	64.65		587,239	76.32
Cancelled	(145,205)	49.03		(198,740)	57.21
Vested	(386,616)	32.64		(403,223)	50.48
Unvested at December 31, 2022	1,045,202	\$ 54.89			
Unvested at December 31, 2023				1,030,478	\$ 68.38
Granted	515,202	76.53		366,652	79.36
Cancelled	(175,705)	56.55		(20,668)	65.79
Vested	(373,983)	49.44		(192,282)	57.59
Unvested at September 30, 2023	1,010,716	\$ 67.65			
Unvested at March 31, 2024				1,184,180	\$ 73.57

1615

Restricted Performance stock unit activity during 2022 2023 and 2023 2024 was as follows:

	Weighted		Weighted	
	Average		Average	
	Number of Units	Grant-Date Fair Value	Number of Units	Grant-Date Fair Value
Unvested at January 1, 2022	1,504,420	\$ 23.20		
Unvested at January 1, 2023			1,273,800	\$ 20.69
Granted	105,311	73.96	177,509	70.98
Performance adjustment	182,543	33.05	407,825	17.69
Cancelled	—	—	(114,908)	69.07
Vested	(518,474)	43.16	(1,408,195)	10.60
Unvested at December 31, 2022	1,273,800	\$ 20.69		
Unvested at December 31, 2023			336,031	\$ 69.35
Granted	177,509	70.98	—	—
Performance adjustment	388,124	15.47	(9,241)	72.99
Cancelled	(114,908)	69.07	(98,504)	61.52
Vested	(1,408,195)	10.60	—	—
Unvested at September 30, 2023	316,330	\$ 69.84		
Unvested at March 31, 2024			228,286	\$ 72.58

Restricted stock unit awards are time-based vesting awards that vest over a period of three or four years and are subject to continuing service of the employee or non-employee director over the ratable vesting periods. The fair values of the restricted stock unit awards were determined based on the closing price of the Company's common stock on the trading date immediately prior to the grant date.

Restricted Performance stock units are granted to employees and are subject to Company performance compared to pre-established targets. In addition to Company performance, these performance-based restricted performance stock units are subject to the continuing service of the employee during the three-year period covered by the awards. The performance condition for the restricted performance stock units is based on the Company's achievement of annually established targets for diluted earnings per share. The number of shares issuable at the end of the applicable vesting period of restricted stock units ranges from 0% to 200% of the targeted units based on the Company's actual performance compared to the targets.

The fair values of restricted performance stock units were determined based on the closing price of the Company's common stock on the trading date immediately prior to the grant date for units subject to performance conditions.

16. Transaction, legal and other costs

Transaction, legal and other costs represent costs primarily related to legal, accounting, termination, restructuring, management transition, acquisition and other similar costs. Transaction, legal and other costs comprised the following costs for the three months ended March 31, 2024 and 2023 (in thousands):

Three Months Ended March 31,

	2024	2023
Legal, accounting and other acquisition-related costs	\$ 5,238	\$ 1,640
Management transition costs	1,009	4,800
Termination and restructuring	(3,400)	31
	<u>\$ 2,847</u>	<u>\$ 6,471</u>

17. Income Taxes

The provision for income taxes for the three months ended September 30, 2023 March 31, 2024 and 2022 2023 reflects effective tax rates of 25.0 20.3% and 24.8 22.3%, and 28.4% and 24.2% for the nine months ended September 30, 2023 and 2022, respectively.

As the Company continues to monitor the implications of potential tax legislation in each of its jurisdictions, the Company may adjust estimates and record additional amounts for tax assets and liabilities. Any adjustments to the Company's tax assets and liabilities could materially impact the provision for income taxes and its effective tax rate in the periods in which they are made.

16

17.18 Fair Value Measurements

The carrying amounts reported for cash and cash equivalents, accounts receivable, other current assets, accounts payable and other current liabilities approximate fair value because of the short-term maturity of these instruments.

The carrying amounts and fair values of the Credit Facility, 5.500% Senior Notes and 5.000% Senior Notes at September 30, 2023 March 31, 2024 and December 31, 2022 December 31, 2023 were as follows (in thousands):

	Carrying Amount				Fair Value				Carrying Amount				Fair Value			
	Septembe		Decembe		Septembe		Decembe		March 31,		December 31,		March 31,		December 31,	
	r 30,		r 31,		r 30,		r 31,		2024		2023		2024		2023	
	2023	2022	2023	2022	2023	2022	2023	2022	2024	2023	2023	2022	2024	2023	2023	2022
Credit Facility	461,03	471,4	461,03	471,4												
5.500% Senior Notes	\$ 3	\$ 89	\$ 3	\$ 89	\$ 939,450	\$ 455,880	\$ 939,450	\$ 455,880								
due 2028	445,32	444,6	416,37	422,4												
	\$ 5	\$ 94	\$ 9	\$ 59	\$ 445,760	\$ 445,539	\$ 433,502	\$ 436,628								

5.000% Senior Notes due 2029	470,15	469,6	423,75	433,2	\$ 9 \$ 09	\$ 4 \$ 14	\$ 470,538	\$ 470,348	\$ 444,658	\$ 451,534
------------------------------	--------	-------	--------	-------	------------	------------	------------	------------	------------	------------

The Credit Facility, 5.500% Senior Notes and 5.000% Senior Notes were categorized as Level 2 in the GAAP fair value hierarchy. Fair values were based on trading activity among the Company's lenders and the average bid and ask price as determined using published rates.

17

18. Subsequent Events

See Note 12 – Commitments and Contingencies for a discussion of developments related to the Cases following September 30, 2023.

18

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

This Quarterly Report on Form 10-Q contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include any statements that address future results or occurrences. In some cases, you can identify forward-looking statements by terminology such as "may," "might," "will," "would," "should," "could" or the negative thereof. Generally, the words "anticipate," "believe," "continue," "expect," "intend," "estimate," "project," "plan" and similar expressions identify forward-looking statements. In particular, statements about our expectations, beliefs, plans, objectives, assumptions or future events or performance are forward-looking statements.

We have based these forward-looking statements on our current expectations, assumptions, estimates and projections. While we believe these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks, uncertainties and other factors, many of which are outside of our control, which could cause our actual results, performance or achievements to differ materially from any results, performance or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and other factors include, but are not limited to:

- the impact of competition for staffing, labor shortages and higher turnover rates on our labor costs and profitability;
- the impact of increases in inflation and rising interest rates; rate volatility;
- compliance with laws and government regulations;

- our indebtedness, our ability to meet our debt obligations, and our ability to incur substantially more debt;
- the impact of payments received from the government and third-party payors on our revenue and results of operation
- the impact of volatility in the global capital and credit markets, as well as significant developments in macroeconomic and political conditions that are out of our control;
- the impact of general economic and employment conditions, including increased construction and other costs due to inflation, on our business and future results of operations;
- difficulties in successfully integrating the operations of acquired facilities or realizing the potential benefits and synergies of our acquisitions and joint ventures;
- our ability to recruit and retain quality psychiatrists and other physicians, nurses, counselors and other medical support personnel;
- the occurrence of patient incidents, which could result in negative media coverage, adversely affect the price of our securities and result in incremental regulatory burdens and governmental investigations;
- the impact of claims brought against us or our facilities including claims for damages for personal injuries, medical malpractice, overpayments, breach of contract, securities law violations, tort and employee related claims;
- the outcome of pending litigation, including litigation;
- the Desert Hills Litigation; impact of carrying a large self-insured retention, the possibilities of being responsible for significant amounts not covered by insurance, premium increases and insurance not being available on acceptable terms because of our claims experience;
- the impact of governmental investigations, regulatory actions and whistleblower lawsuits;
- any failure to comply with the terms of our corporate integrity agreement with the OIG;
- the impact of healthcare reform in the U.S.;
- our acquisition, joint venture and wholly-owned de novo strategies, which expose us to a variety of operational and financial risks, as well as legal and regulatory risks;
- the impact of state efforts to regulate the construction or expansion of healthcare facilities on our ability to operate and expand our operations;
- our ability to implement our business strategies;
- the impact of Medicaid eligibility determinations associated with the end of COVID-related COVID-19 related Medicaid continuing coverage requirements;
- the impact of disruptions on our inpatient and outpatient volumes caused by pandemics, epidemics or outbreaks of infectious diseases, such as the COVID-19 pandemic;

1918

- our dependence on key management personnel, key executives and local facility management personnel, and the impact of any disruptions from the recent transition of various executives;
- our restrictive covenants, which may restrict our business and financing activities;
- the impact of adverse weather conditions and climate change, including the effects of hurricanes, wildfires and other natural disasters, and any resulting outmigration;
- the risk of a cyber-security incident and any resulting adverse impact on our operations or violation of laws and regulations regarding information privacy;
- the impact on our business if our information systems fail or our databases are destroyed or damaged;
- our future cash flow and earnings;
- the impact of our highly competitive industry on patient volumes;
- our ability to cultivate and maintain relationships with referral sources;
- the impact of the trend for insurance companies and managed care organizations to enter into sole source contracts with our ability to obtain patients;
- the impact of value-based purchasing programs on our revenue;
- our potential inability to extend leases at expiration;
- the impact of controls designed to reduce inpatient services on our revenue;
- the impact of different interpretations of accounting principles on our results of operations or financial condition;
- the impact of environmental, health and safety laws and regulations, especially in locations where we have concentrated operations;
- the impact of laws and regulations relating to privacy and security of patient health information and standards for electronic transactions;
- the impact of a change in the mix of our earnings, adverse changes in our effective tax rate and adverse developments in tax laws generally;
- changes in interpretations, assumptions and expectations regarding recent tax legislation, including provisions of the CARES Act and additional guidance that may be issued by federal and state taxing authorities;
- failure to maintain effective internal control over financial reporting;
- the impact of fluctuations in our operating results, quarter to quarter earnings and other factors on the price of our securities; and
- those risks and uncertainties described from time to time in our filings with the SEC.

Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. These risks and uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements. These forward-looking statements are made only as of the date of this

Quarterly Report on Form 10-Q. We do not undertake and specifically decline any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments.

Overview

Our business strategy is to **acquire and develop** become the indispensable behavioral healthcare **facilities** provider for the high-acuity and **improve our operating results** within our facilities and our other behavioral healthcare **operations**. complex needs patient population. We **strive** are committed to **improve** providing the operating results of our facilities by providing communities we serve with high-quality, **services**, **expanding referral networks** and **marketing** initiatives while meeting the increased demand for **cost-effective** behavioral healthcare services, **through** while growing our business, increasing profitability and creating long-term value for our stockholders. This strategy includes five growth pathways: expansions of existing facilities, joint venture partnerships, de novo facilities, acquisitions and expansion across our continuum of our current locations as well as developing new services within existing locations. care. At **September 30, 2023** **March 31, 2024**, we operated **253** **258** behavioral healthcare facilities with approximately **11,100** **11,300** beds in **39** **38** states and Puerto Rico. During the **nine** **three** months ended **September 30, 2023** **March 31, 2024**, we added **396** **47** beds, consisting of **204** **27** beds to existing facilities and **192** **20** beds added through the opening of two joint venture facilities, and we opened four CTCs, a wholly-owned facility. For the year ending **December 31, 2023** **December 31, 2024**, we expect to add approximately **300** **1,200** total beds through additions and open up to existing facilities, and we expect to open two wholly-owned facilities, two joint venture facilities and six CTCs. **14** CTCs, excluding acquisitions.

2019

We are the leading publicly traded pure-play provider of behavioral healthcare services in the U.S. Management believes that we are positioned as a leading platform in a highly fragmented industry under the direction of an experienced management team that has significant **healthcare** industry expertise. Management expects to take advantage of several strategies that are more accessible as a result of our increased size and geographic scale, including continuing a national marketing strategy to attract new patients and referral sources, increasing our volume of out-of-state referrals, providing a broader range of services to new and existing patients and clients and selectively pursuing opportunities to expand our facility and bed count in the U.S. through acquisitions, wholly-owned de novo facilities, joint ventures and bed additions in existing facilities.

COVID-19

During March 2020, the global pandemic of COVID-19 began to affect our facilities, employees, patients, communities, business operations and financial performance, as well as the broader U.S. economy and financial market. At many of our facilities, employees and/or patients have tested positive for COVID-19. We are committed to protecting the health of our communities and have been responding to the evolving COVID-19 situation while taking steps to provide quality care and protect the health and safety of our patients and employees. Over the last three years, all of our facilities have closely followed infectious disease protocols, as well as recommendations by the Centers for Disease Control and Prevention and local health officials.

CARES Act and Other Regulatory Matters

On March 27, 2020, the CARES Act was signed into law. The CARES Act is intended to provide over \$2 trillion in stimulus benefits for the U.S. economy. Among other things, the CARES Act includes additional support for small businesses, expands unemployment benefits, makes forgivable loans available to small businesses, provides for certain federal income tax changes, and provides \$500 billion for loans, loan guarantees, and other investments for or in U.S. businesses.

In addition, the CARES Act contains a number of provisions that are intended to assist healthcare providers as they combat the effects of the COVID-19 pandemic. Those provisions include, among others:

- an appropriation to the PHSSE Fund, also known as the Provider Relief Fund, to reimburse, through grants or other mechanisms, eligible healthcare providers and other approved entities for COVID-19-related expenses or lost revenue;
- the expansion of CMS' Accelerated and Advance Payment Program;
- the temporary suspension of Medicare sequestration from May 1, 2020 to March 31, 2022, which was reduced to 1% on April 1, 2022 and was eliminated effective July 1, 2022; and
- waivers or temporary suspension of certain regulatory requirements.

The U.S. government initially announced it would offer \$100 billion of relief to eligible healthcare providers through the PHSSE Fund. On April 24, 2020, then President Trump signed into law the PPP Act. Among other things, the PPP Act allocated \$75 billion to eligible healthcare providers to help offset COVID-19 related losses and expenses. The \$75 billion allocated under the PPP Act was in addition to the \$100 billion allocated to healthcare providers for the same purposes in the CARES Act and has been disbursed to providers under terms and conditions similar to the CARES Act funds. In 2020, we received approximately \$34.9 million of the funds distributed from the PHSSE Fund. During the fourth quarter of 2020, we recorded approximately \$32.8 million of income from provider relief fund related to PHSSE Fund amounts received in 2020.

In 2021, we received \$24.2 million of additional funds from the PHSSE Fund. During the fourth quarter of 2021, we recorded \$17.9 million of income from provider relief fund related to the PHSSE Fund amounts received. During the year ended December 31, 2022, we received \$7.7 million of additional funds from the PHSSE Fund and \$14.2 million from the ARP Rural Payments for Hospitals. During the year ended December 31, 2022, we recorded \$21.5 million of income from provider relief fund related to PHSSE Fund and ARP funds received. During the third quarter of 2023, we recorded \$4.4 million of income from provider relief fund related to ARP funds received. The remaining unrecognized funds of \$4.5 million

and \$9.0 million are included in other accrued liabilities on the condensed consolidated balance sheets as of September 30, 2023 and December 31, 2022, respectively. We continue to evaluate our compliance with the terms and conditions to, and the financial impact of, these additional funds received, including potential repayment of the remaining balance.

Healthcare providers were required to sign an attestation confirming receipt of the PHSSE Fund amounts and agree to the terms and conditions of payment. Under the terms and conditions for receipt of the payment, we were allowed to use the funds to cover lost revenues and healthcare costs related to COVID-19, and we were required to properly and fully document the use of these funds to the U.S. Department of Health and Human Services. The reporting of the funds is subject to future audit for compliance with the terms

21

and conditions. We recognized PHSSE Fund amounts to the extent we had qualifying COVID-19 expenses or lost revenues as permitted under the terms and conditions.

During 2020, we applied for and received approximately \$45.2 million of payments from the CMS Accelerated and Advance Payment Program. Of the \$45.2 million of advance payments received in 2020, we repaid approximately \$25.1 million of advance payments during 2021 and made additional repayments of approximately \$20.1 million during the year ended December 31, 2022 to eliminate the liability.

Under the CARES Act, we received a 2% increase in our facilities' Medicare reimbursement rate as a result of the temporary suspension of Medicare sequestration from May 1, 2020 to March 31, 2022, which was reduced to 1% on April 1, 2022 and was eliminated effective July 1, 2022.

The CARES Act also provided for certain federal income and other tax changes. We received a cash benefit of approximately \$39.3 million for 2020 relating to the delay of payment of the employer portion of Social Security payroll taxes. We repaid half of the \$39.3 million of payroll tax deferrals during the third quarter of 2021 and repaid the remaining portion in the third quarter of 2022 to eliminate the liability.

These regulatory changes were temporary and expired at the end of the COVID-19 public health emergency on May 11, 2023.

We are continuing to evaluate the terms and conditions and financial impact of funds received under the CARES Act and other government relief programs.

Results of Operations

The following table illustrates our consolidated results of operations for the respective periods shown (dollars in thousands):

Three Months Ended	Nine Months Ended	Three Months Ended
September 30,	September 30,	March 31,

	2023		2022		2023		2022		2024		2023	
	Amo		Amo		Amo		Amo					
	unt	%	unt	%	unt	%	unt	%	Amount	%	Amount	%
Revenue			6									
	1	6	1	2,	1	1	1,	1				
	75	0	6,	0	18	0	93	0				
	0,	0	7	0	5,	0	5,	0				
	33	.	3	.	93	.	10	.				
	\$ 4	0%	\$ 2	0%	\$ 8	0%	\$ 4	0%	\$ 768,051	100.0%	\$ 704,267	100.0%
Salaries, wages and benefits			3									
			5									
	39	5	2,	5	17	5	02	5				
	4,	2	5	2	1,	3	7,	3				
	15	.	8	.	96	.	73	.				
	0	5%	2	9%	0	6%	2	1%	417,523	54.4%	391,177	55.6%
Professional fees			4									
			0,									
	45	6	3	6	0,	6	7,	6				
	,5	.	6	.	46	.	71	.				
	40	1%	7	1%	8	0%	8	1%	45,688	5.9%	41,125	5.8%
Supplies			2									
			5,									
	27	3	5	3	79	3	74	3				
	,1	.	7	.	,3	.	,2	.				
	47	6%	0	8%	12	6%	91	8%	26,652	3.5%	26,021	3.7%
Rents and leases			1									
			1,									
	11	1	3	1	34	1	33	1				
	,7	.	3	.	,8	.	,7	.				
	31	6%	9	7%	80	6%	80	7%	11,863	1.5%	11,424	1.6%
Other operating expenses			8									
	10	1	8,	1	29	1	25	1				
	4,	3	9	3	0,	3	5,	3				
	04	.	9	.	79	.	35	.				
	8	9%	3	3%	8	3%	5	2%	101,073	13.2%	90,838	12.9%

	-	(7	-	-	(1	-						
Income from provider relief fund	(40,42)	6%	,6	1	(4	0	6,	0				
			5	.	,4	.	20	.				
	42)	6%	6)	1%	42)	2%	6)	8%				
			2									
			9,									
Depreciation and amortization	33,88	4%	4	5	4	96	4	87	4			
	,3	.	.	7	.	,9	.	,6	.			
	88	4%	3	4%	69	4%	27	5%				
			1									
			8,									
Interest expense, net	20,42	2%	0	2	61	2	50	2				
	,7	.	0	.	,6	.	,3	.				
	42	8%	3	7%	51	8%	55	6%				
			39	5		39	1					
Legal settlements expense	4,18	2%	2	0	4,	8		0				
	18	.		.				
	1	5%	—	0%	1	0%	—	0%				
	0		0	8,	0			0				
Loss on impairment	69	.	.	.				
	—	0%	—	0%	4	4%	—	0%				
			1									
			0,									
Transaction-related expenses	11,47	1%	8	1	26	1	18	0				
	,2	.	5	.	,7	.	,3	.				
	47	5%	9	6%	92	2%	81	9%				
Transaction, legal and other costs									2,847	0.4%	6,471	0.9%
			5									
	1,03	1	6		2,	1	1,					
	3	3	9,	8	29	0	64	8				
	7,	8	6	5	1,	4	9,	5				
	73	.	3	.	26	.	03	.				
Total expenses	2	3%	0	4%	3	7%	3	1%	669,207	87.1%	618,624	87.8%

	-	9						
	(2	3	7,	1	(1	-	28	1
(Loss) income	87	8	1	4	05	4	6,	4
before income	,3	.	0	.	,3	.	07	.
taxes	98)	3%	2	6%	25)	7%	1	9%
		2						
	(7	-	4,		(2	-		
(Benefit from)	1,	9	0	3	9,	1	69	3
provision for	87	.	5	.	90	.	,1	.
income taxes	3)	6%	6	6%	7)	3%	83	6%
	-	7						
	(2	2	3,	1	(7	-	21	1
	15	8	0	1	5,	3	6,	1
	,5	.	4	.	41	.	88	.
Net (loss) income	25)	7%	6	0%	8)	5%	8	3%
Income before								
income taxes							98,844	12.9%
Provision for								
income taxes							20,074	2.6%
Net income							78,770	10.3%
Net income	-	(1	-	-	-	-		
attributable to	(2	0	,9	0	(3	0	(4	0
noncontrolling	,1	.	4	.	,9	.	,8	.
interests	85)	3%	7)	3%	78)	2%	73)	3%
	-	7					(2,387)	-0.4%
Net (loss) income	(2	2	1,	1	(7	-	21	1
attributable to	17	9	0	0	9,	3	2,	1
Acadia Healthcare	,7	.	9	.	39	.	01	.
Company, Inc.	\$ 10)	0%	\$ 9	7%	\$ 6)	6%	\$ 5	0%
Net income								
attributable to								
Acadia Healthcare								
Company, Inc.							\$ 76,383	9.9%
							\$ 66,015	9.4%

We believe that we are well positioned to help meet the growing demand for behavioral **health** **healthcare** services and we recorded a revenue growth rate of 13.0% 9.1% for the **nine** **three** months ended **September 30, 2023** **March 31, 2024** compared to the **nine** **three** months ended **September 30, 2022** **March 31, 2023**. Similar to with many other healthcare

providers and other industries across the country, we continue to navigate a tight labor market. While we experienced higher wage inflation **in the nine months ended September 30, 2023** recently compared to long-term historical averages, we have seen stability in our labor costs and our proactive focus helps us manage through this environment. We remain focused on ensuring that we have the level of staff to meet the demand in our markets across **our 39** **38** states and Puerto Rico.

22 **20**

The following table sets forth percent changes in same facility operating data for the three **and nine** months ended **September 30, 2023** **March 31, 2024** compared to the same **periods** **period** in **2022** **2023**:

	Three Months Ended	Nine Months Ended
Same Facility Results (a)		
Revenue growth	13.0%	12.5%
Patient days growth	6.0%	5.8%
Admissions growth	5.1%	6.0%
Average length of stay change (b)	0.9%	-0.1%
Revenue per patient day growth	6.6%	6.4%
Adjusted EBITDA margin change (c)	20 bps	30 bps
Adjusted EBITDA margin excluding income from provider relief fund (d)	80 bps	90 bps

Same Facility Results (a)	
Revenue growth	9.2%
Patient days growth	2.2%
Admissions growth	-1.7%
Average length of stay change (b)	4.0%
Revenue per patient day growth	6.9%
Adjusted EBITDA margin change (c)	120 bps

(a) Results for the periods presented include facilities we have operated more than one year and exclude certain closed services.

(b) Average length of stay is defined as patient days divided by admissions.

(c) Adjusted EBITDA is defined as income before provision for income taxes, equity-based compensation expense, **loss on impairment, transaction-related expenses, transaction, legal and other costs, interest expense, legal settlements** expense and depreciation and amortization. Management uses Adjusted EBITDA as an analytical indicator to measure performance and to develop strategic objectives and operating plans. Adjusted EBITDA is commonly used as an analytical indicator within the health care industry, and also serves as a measure of leverage capacity and debt service ability. Adjusted EBITDA should not be considered as a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures of other companies.

(d) For each of the three and nine months ended September 30, 2023, excludes income from provider relief fund of \$4.4 million. For the three and nine months ended September 30, 2022, excludes income from provider relief fund of \$7.7 million and \$16.2 million, respectively. **Adjusted EBITDA margin is defined as Adjusted EBITDA divided by revenue.**

Three months ended September 30, 2023 March 31, 2024 compared to the three months ended September 30, 2022 March 31, 2023

Revenue. Revenue increased \$83.6 million \$63.8 million, or 12.5% 9.1%, to \$750.3 million \$768.1 million for the three months ended September 30, 2023 March 31, 2024 from \$666.7 million \$704.3 million for the three months ended September 30, 2022 March 31, 2023. Same facility revenue increased \$85.5 million \$63.8 million, or 13.0% 9.2%, for the three months ended September 30, 2023 March 31, 2024 compared to the three months ended September 30, 2022 March 31, 2023, resulting from an increase in same facility revenue per day of 6.6%, 6.9% and same facility growth in patient days of 6.0% and same facility growth in admissions of 5.1% 2.2%. Consistent with same facility revenue growth in 2022, 2023, the growth in same facility patient days for the three months ended September 30, 2023 March 31, 2024 compared to the three months ended September 30, 2022 March 31, 2023 resulted from the addition of beds to our existing facilities and ongoing demand for our services.

Salaries, wages and benefits. Salaries, wages and benefits ("SWB") expense was \$394.2 million \$417.5 million for the three months ended September 30, 2023 March 31, 2024 compared to \$352.6 million \$391.2 million for the three months ended September 30, 2022 March 31, 2023, an increase of \$41.6 million \$26.3 million. SWB expense included \$8.2 million \$8.7 million and \$7.2 million \$7.6 million of equity-based compensation expense for the three months ended September 30, 2023 March 31, 2024 and 2022, 2023, respectively. Excluding equity-based compensation expense, SWB expense was \$386.0 million \$408.8 million, or 51.4% 53.2% of revenue, for the three months ended September 30, 2023 March 31, 2024, compared to \$345.4 million \$383.6 million, or 51.8% 54.5% of revenue, for the three months ended September 30, 2022 March 31, 2023. The increase in SWB expense relates to incremental staff to support volume growth as well as wage inflation. Same facility SWB expense was \$352.0 million \$368.7 million for the three months ended September 30, 2023 March 31, 2024, or 47.3% 48.7% of revenue, compared to \$315.9 million \$344.1 million for the three months ended September 30, 2022 March 31, 2023, or 47.9% 49.7% of revenue.

Professional fees. Professional fees were \$45.5 million \$45.7 million for the three months ended September 30, 2023 March 31, 2024, or 6.1% 5.9% of revenue, compared to \$40.4 million \$41.1 million for the three months ended

September 30, 2022 March 31, 2023, or 6.1% 5.8% of revenue. Same facility professional fees were \$40.7 million \$39.9 million for the three months ended September 30, 2023 March 31, 2024, or 5.5% 5.3% of revenue, compared to \$36.9 million \$37.1 million for the three months ended September 30, 2022 March 31, 2023, or 5.6% 5.4% of revenue.

23

Supplies. Supplies expense was \$27.1 million for the three months ended September 30, 2023, or 3.6% of revenue, compared to \$25.6 million for the three months ended September 30, 2022, or 3.8% of revenue. Same facility supplies expense was \$26.7 million for the three months ended September 30, 2023 March 31, 2024, or 3.6% 3.5% of revenue, compared to \$25.2 million \$26.0 million for the three months ended September 30, 2022 March 31, 2023, or 3.8% 3.7% of revenue. Same facility supplies expense was \$26.0 million for the three months ended March 31, 2024, or 3.4% of revenue, compared to \$25.4 million for the three months ended March 31, 2023, or 3.7% of revenue.

Rents and leases. Rents and leases were \$11.7 million \$11.9 million for the three months ended September 30, 2023 March 31, 2024, or 1.6% 1.5% of revenue, compared to \$11.3 million \$11.4 million for the three months ended September 30, 2022 March 31, 2023, or 1.7% 1.6% of revenue. Same facility rents and leases were \$10.6 million \$10.8 million for the three months ended September 30, 2023 March 31, 2024, or 1.4% of revenue, compared to \$10.5 million for the three months ended September 30, 2022 March 31, 2023, or 1.6% 1.5% of revenue.

Other operating expenses. Other operating expenses consisted primarily of purchased services, utilities, insurance, travel and repairs and maintenance expenses. Other operating expenses were \$104.0 million \$101.1 million for the three months ended September 30, 2023 March 31, 2024, or 13.9%

21

13.2% of revenue, compared to \$89.0 million \$90.8 million for the three months ended September 30, 2022 March 31, 2023, or 13.3% 12.9% of revenue. Same facility other operating expenses were \$97.2 million \$93.9 million for the three months ended September 30, 2023 March 31, 2024, or 13.1% 12.4% of revenue, compared to \$83.3 million \$84.9 million for the three months ended September 30, 2022 March 31, 2023, or 12.6% 12.3% of revenue.

Income from provider relief fund. For the three months ended September 30, 2023, we recorded \$4.4 million in income from provider relief fund related to ARP funds received in 2022, compared to \$7.7 million in income from provider relief fund related to PHSSE Fund amounts received in 2022 for the three months ended September 30, 2022.

Depreciation and amortization. Depreciation and amortization expense was \$33.4 million \$36.3 million for the three months ended September 30, 2023 March 31, 2024, or 4.4% 4.7% of revenue, compared to \$29.6 million \$31.6 million for the three months ended September 30, 2022 March 31, 2023, or 4.4% 4.5% of revenue.

Interest expense. Interest expense was \$20.7 million for the three months ended September 30, 2023, compared to \$18.0 million for the three months ended September 30, 2022. The increase in interest expense was primarily the result of higher interest rates applicable to our variable rate debt borrowings under the Credit Facility during the first quarter of 2024.

Legal settlements expense Transaction, legal and other costs. Legal settlements expense Transaction, legal and other costs were \$2.8 million for the three months ended September 30, 2023 was \$394.2 million associated with the Desert Hills Litigation.

Transaction-related expenses. Transaction-related expenses were \$11.2 million for the three months ended September 30, 2024, compared to \$6.5 million for the three months ended September 30, 2023, compared to \$10.9 million for the three months ended September 30, 2022. Transaction-related expenses Transaction, legal and other costs represent legal, accounting, termination, restructuring, management transition, acquisition and other similar costs incurred in the respective period, as summarized below (in thousands).

	Three Months Ended September 30,	
	2023	2022
Legal, accounting and other acquisition-related costs	\$ 4,196	\$ 2,020
Management transition costs	3,615	5,626
Termination and restructuring costs	3,436	3,213
	<u>\$ 11,247</u>	<u>\$ 10,859</u>
Three Months Ended March 31,		
	2024	2023
	\$ 5,238	\$ 1,640
Management transition costs	1,009	4,800
Termination and restructuring	(3,400)	31
	<u>\$ 2,847</u>	<u>\$ 6,471</u>

(Benefit from) provision Provision for income taxes. For the three months ended September 30, 2023 March 31, 2024, the benefit from income taxes was \$(71.9) million, reflecting an effective tax rate of 25.0%, compared to the provision for income taxes of \$24.1 million was \$20.1 million, reflecting an effective tax rate of 24.8%, for the three months ended September 30, 2022.

As we continue to monitor the implications of potential tax legislation in each of our jurisdictions, we may adjust our estimates and record additional amounts for tax assets and liabilities. Any adjustments to our tax assets and liabilities could materially impact our provision for income taxes and our effective tax rate in the periods in which they are made.

Nine months ended September 30, 2023 compared to the nine months ended September 30, 2022

Revenue. Revenue increased \$250.8 million, or 13.0%, to \$2,185.9 million for the nine months ended September 30, 2023 from \$1,935.1 million for the nine months ended September 30, 2022. Same facility revenue increased \$240.9 million, or 12.5%, for the nine months ended September 30, 2023 compared to the nine months ended September 30, 2022, resulting from an increase in same facility revenue per day of 6.4%, same facility growth in admissions of 6.0% and same facility growth in patient days of 5.8%. Consistent with same facility revenue growth in 2022, the growth in same facility patient days for the nine months ended September 30, 2023 compared to the nine months ended September 30, 2022 resulted from the addition of beds to our existing facilities and ongoing demand for our services.

Salaries, wages and benefits. SWB expense was \$1,172.0 million for the nine months ended September 30, 2023 compared to \$1,027.7 million for the nine months ended September 30, 2022, an increase of \$144.2 million. SWB expense included \$23.1 million and \$21.7 million of equity-based compensation expense for the nine months ended September 30, 2023 and 2022, respectively. Excluding equity-based compensation expense, SWB expense was \$1,148.8 million, or 52.6% of revenue, for the nine months ended September 30, 2023 20.3%, compared to \$1,006.0 million, or 52.0% of revenue, for the nine months ended September 30, 2022. The increase in SWB expense relates to incremental staff to support volume growth as well as wage inflation. Same facility SWB expense was \$1,040.6 million for the nine months ended September 30, 2023, or 48.2% of revenue, compared to \$927.2 million for the nine months ended September 30, 2022, or 48.3% of revenue.

Professional fees. Professional fees were \$130.5 million for the nine months ended September 30, 2023, or 6.0% of revenue, compared to \$117.7 million for the nine months ended September 30, 2022, or 6.1% of revenue. Same facility professional fees were \$116.0 million for the nine months ended September 30, 2023, or 5.4% of revenue, compared to \$108.2 million for the nine months ended September 30, 2022, or 5.6% of revenue.

Supplies. Supplies expense was \$79.3 million for the nine months ended September 30, 2023, or 3.6% of revenue, compared to \$74.3 million for the nine months ended September 30, 2023, or 3.8% of revenue. Same facility supplies expense was \$77.9 million for the nine months ended September 30, 2023, or 3.6% of revenue, compared to \$73.5 million for the nine months ended September 30, 2022, or 3.8% of revenue.

Rents and leases. Rents and leases were \$34.9 million for the nine months ended September 30, 2023, or 1.6% of revenue, compared to \$33.8 million for the nine months ended September 30, 2022, or 1.7% of revenue. Same facility rents and leases were \$31.9 million for the nine months ended September 30, 2023, or 1.5% of revenue, compared to \$31.5 million for the nine months ended September 30, 2022, or 1.6% of revenue.

Other operating expenses. Other operating expenses consisted primarily of purchased services, utilities, insurance, travel and repairs and maintenance expenses. Other operating expenses were \$290.8 million for the nine months ended September 30, 2023, or 13.3% of revenue, compared to \$255.4 million for the nine months ended September 30, 2022, or 13.2% of revenue. Same facility other operating expenses were \$270.5 million for the nine months ended September 30,

2023, or 12.5% of revenue, compared to \$242.9 million for the nine months ended September 30, 2022, or 12.6% of revenue.

Income from provider relief fund. For the nine months ended September 30, 2023, we recorded \$4.4 million in income from provider relief fund related to ARP funds received in 2022, compared to \$16.2 million in income from provider relief fund related to PHSSE Fund amounts and ARP funds received in 2021 and 2022 for the nine months ended September 30, 2022.

Depreciation and amortization. Depreciation and amortization expense was \$97.0 million for the nine months ended September 30, 2023, or 4.4% of revenue, compared to \$87.6 million for the nine months ended September 30, 2022, or 4.5% of revenue.

Interest expense. Interest expense was \$61.7 million for the nine months ended September 30, 2023, compared to \$50.4 million for the nine months ended September 30, 2022. The increase in interest expense was primarily a result of higher interest rates applicable to our variable rate debt.

Legal settlements expense. Legal settlements expense for the nine months ended September 30, 2023 was \$394.2 million associated with the Desert Hills Litigation.

25

Loss on impairment. During the second quarter of 2023, we recorded non-cash impairment charges totaling \$8.7 million related to the closure of certain facilities. The non-cash impairment charges include an indefinite-lived intangible asset impairment of \$4.7 million, property impairment of \$2.0 million and operating lease right-of-use asset impairment of \$2.0 million.

Transaction-related expenses. Transaction-related expenses were \$26.8 million for the nine months ended September 30, 2023, compared to \$18.4 million for the nine months ended September 30, 2022. Transaction-related expenses represent legal, accounting, termination, restructuring, management transition, acquisition and other similar costs incurred in the respective period, as summarized below (in thousands).

	Nine Months Ended September 30,	
	2023	2022
Management transition costs	\$ 14,590	\$ 7,826
Legal, accounting and other acquisition-related costs	6,761	4,696
Termination and restructuring costs	5,441	5,859
	\$ 26,792	\$ 18,381

(Benefit from) provision for income taxes. For the nine months ended September 30, 2023, the benefit from income taxes was \$(29.9) million, reflecting an effective tax rate of 28.4%, compared to the provision for income taxes of \$69.2

million \$19.1 million, reflecting an effective tax rate of 24.2% 22.3%, for the nine months ended September 30, 2022 March 31, 2023.

As we continue to monitor the implications of potential tax legislation in each of our jurisdictions, we may adjust our estimates and record additional amounts for tax assets and liabilities. Any adjustments to our tax assets and liabilities could materially impact our provision for income taxes and our effective tax rate in the periods in which they are made.

Revenue

Our revenue is primarily derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care and adolescent residential treatment. We receive payments from the following sources for services rendered in our facilities: (i) state governments under their respective Medicaid and other programs; (ii) commercial insurers; (iii) the federal government under the Medicare program administered by CMS; CMS and other programs; and (iv) individual patients and clients. We determine the transaction price based on established billing rates reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients and implicit price concessions. Contractual adjustments and discounts are based on contractual agreements, discount policies and historical experience. Implicit price concessions are based on historical collection experience.

The following table presents revenue by payor type and as a percentage of revenue for the three and nine months ended September 30, 2023 March 31, 2024 and 2022 2023 (dollars in thousands):

	Three Months Ended				Nine Months Ended				Three Months Ended			
	September 30,		September 30,		September 30,		September 30,		March 31,		March 31,	
	2023	2022	2023	2022	2023	2022	2023	2022	2024	2023	2024	2023
Am	Am	Am	Am	Am	Am	Am	Am	Am	Amount	Amount	Amount	Amount
ou	ou	ou	oun	oun	oun	oun	oun	oun	%	%	%	%
nt	%	nt	%	nt	%	nt	%	nt				
C	2	1	6	5								
o	1	9	2	9								
m	2	3	5	0								
m	, 2	, 2	, 2	, 3								
er	3 8	6 9	3 8	9 0								
ci	2 .	2 .	3 .	6 .								
al	\$ 8	3%	\$ 6	0%	\$ 0	6%	\$ 6	5%	\$ 196,017	25.5 %	\$ 203,619	28.9 %

	1	1	3	2								
M	1	0	3	9								
e	7	1	5	3								
di	,	1	,	1	,	1						
c	3	5	2	5	8	5	3	5				
ar	4	.	4	.	1	.	3	.				
e	8	6%	6	2%	9	4%	9	2%				
									109,388		108,640	15.4 %
									1			
									,			
									4	3	1	9
M	0		4			5		7				
e	0		3			6		0				
di	,	5	,	5	,	5	,	5				
c	4	3	0	1	7	2	5	0				
ai	8	.	6	.	6	.	9	.				
d	3	4%	7	5%	6	9%	1	2%		436,422		364,306
S	1		2			5		5				
el	5		0			2		8				
f-	,		,		,	,		,				
P	5	2	0	3	0	2	3	3				
a	2	.	1	.	2	.	9	.				
y	4	1%	3	0%	6	4%	0	0%		16,427		20,698
									1	2		
									4	8	5	1
									,	,	,	,
O	6	0	7	1	9	0	8	1				
th	5	.	8	.	9	.	1	.				
er	1	6%	0	3%	7	7%	8	1%		9,797		7,004
									2	1		
									,	,		
R	7		6			1		9				
e	5		6			8		3				
v	0	1	6	1	5	1	5	1				
e	,	0	,	0	,	0	,	0				
n	3	0	7	0	9	0	1	0				
u	3	.	3	.	3	.	0	.				
e	\$ 4	0%	\$ 2	0%	\$ 8	0%	\$ 4	0%	\$	768,051		704,267
										100.0 %		100.0 %

The following tables present a summary of our aging of accounts receivable at **September 30, 2023** **March 31, 2024** and **December 31, 2022** **December 31, 2023**:

September 30, 2023 March 31, 2024

	Current	30-90	90-150	>150	Total
Commercial	18.6 %	5.3 %	3.0 %	9.1 %	36.0 %
Medicare	9.4 %	1.4 %	0.6 %	1.3 %	12.7 %
Medicaid	33.7 %	3.8 %	2.5 %	4.9 %	44.9 %
Self-Pay	1.3 %	1.3 %	1.2 %	2.5 %	6.3 %
Other	0.0 %	0.0 %	0.0 %	0.1 %	0.1 %
Total	63.0 %	11.8 %	7.3 %	17.9 %	100.0 %

	Current	30-90	90-150	>150	Total
Commercial	19.1 %	4.7 %	2.8 %	9.1 %	35.7 %
Medicare	8.8 %	1.8 %	0.5 %	0.8 %	11.9 %
Medicaid	34.3 %	5.2 %	2.1 %	4.3 %	45.9 %
Self-Pay	1.3 %	1.6 %	1.1 %	2.3 %	6.3 %
Other	0.0 %	0.1 %	0.0 %	0.1 %	0.2 %
Total	63.5 %	13.4 %	6.5 %	16.6 %	100.0 %

December 31, 2022 2023

	Current	30-90	90-150	>150	Total
Commercial	18.0 %	5.3 %	2.8 %	8.4 %	34.5 %
Medicare	11.5 %	1.7 %	0.7 %	1.4 %	15.3 %
Medicaid	31.7 %	4.5 %	2.6 %	4.7 %	43.5 %
Self-Pay	1.2 %	1.4 %	1.2 %	2.6 %	6.4 %
Other	0.2 %	0.0 %	0.0 %	0.1 %	0.3 %
Total	62.6 %	12.9 %	7.3 %	17.2 %	100.0 %
	Current	30-90	90-150	>150	Total

	Current	30-50	50-150	>150	Total
Commercial	17.3 %	5.4 %	3.1 %	9.5 %	35.3 %
Medicare	9.3 %	1.4 %	0.5 %	1.1 %	12.3 %
Medicaid	33.4 %	5.4 %	2.5 %	4.7 %	46.0 %
Self-Pay	1.4 %	1.3 %	1.2 %	2.5 %	6.4 %
Other	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Total	61.4 %	13.5 %	7.3 %	17.8 %	100.0 %

Liquidity and Capital Resources

Cash used in operating activities for the three months ended March 31, 2024 was \$321.3 million compared to cash provided by operating activities of \$44.4 million for the nine three months ended September 30, 2023 was \$346.0 million compared to \$267.0 million for the nine months ended September 30, 2022 March 31, 2023. Days sales outstanding were 44 at March 31, 2024 was 46 days compared to 45 days at September 30, 2023 and December 31, 2022 December 31, 2023.

Cash used in investing activities for the nine three months ended September 30, 2023 March 31, 2024 was \$287.1 million \$184.6 million compared to \$213.8 million \$66.9 million for the nine three months ended September 30, 2022 March 31, 2023. Cash used in investing activities for the nine three months ended September 30, 2023 March 31, 2024 primarily consisted of \$285.4 million \$142.4 million of cash paid for capital expenditures, \$1.9 million of other and \$0.3 million \$50.4 million of cash paid for acquisitions net and \$0.9 million of cash acquired, other, offset by \$0.6 million \$9.1 million of proceeds from sales of property and equipment. Cash paid for capital expenditures for the nine three months ended September 30, 2023 March 31, 2024 was \$285.4 million \$142.4 million, consisting of routine or maintenance capital expenditures of \$73.9 million \$22.3 million and expansion capital expenditures of \$211.5 million \$120.1 million. We define expansion capital expenditures as those that increase the capacity of our facilities or otherwise enhance revenue. Routine or maintenance capital expenditures, including information technology capital expenditures, were approximately 3% of revenue for the nine three months ended September 30, 2023 March 31, 2024. Cash used in investing activities for the nine three months ended September 30, 2022 March 31, 2023 primarily consisted of \$208.8 million \$66.5 million of cash paid for capital expenditures and \$6.8 million \$0.8 million of other, offset by \$1.8 million \$0.4 million of proceeds from the sales sales of property and equipment. Cash paid for capital expenditures for the nine three months ended September 30, 2022 March 31, 2023 was \$66.5 million, consisting of routine or maintenance capital expenditures of \$18.0 million and expansion capital expenditures of \$48.5 million.

Cash provided by financing activities for the three months ended March 31, 2024 was \$483.1 million compared to cash used in financing activities of \$11.3 million for the three months ended March 31, 2023. Cash provided by financing activities for the three months ended March 31, 2024 consisted of \$47.0 million borrowings on long-term debt of routine capital expenditures \$350.0 million, borrowings on revolving credit facility of \$160.0 million and \$161.8 million contributions from noncontrolling partners in joint ventures of expansion capital expenditures.

\$2.3 million, offset by principal payments on revolving credit facility of \$15.0 million, principal payments on long-term debt of \$10.2 million, payment of debt issuance costs of \$1.5 million, distributions to noncontrolling partners in joint

ventures of \$1.0 million, repurchase of shares for payroll tax withholding, net of proceeds from stock option exercises of \$1.0 million and \$0.4 million of other. Cash used in financing activities for the **nine** **three** months ended **September 30, 2023** was \$57.0 million compared to \$93.6 million for the nine months ended September 30, 2022. Cash used in financing activities for the nine months ended September 30, 2023 **March 31, 2023** consisted of repurchase of shares for payroll tax withholding, net of proceeds from stock option exercises of \$45.2 million, principal payments on revolving credit facility of \$35.0 million, \$47.7 million and principal payments on long-term debt of \$15.9 million and distributions to noncontrolling partners in joint ventures of \$3.5 million \$5.3 million, offset by borrowings on revolving credit facility of \$40.0 million and contributions from noncontrolling partners in joint ventures of \$2.5 million \$1.7 million. Cash used in financing activities for the nine months ended September 30, 2022 primarily consisted of principal payments on revolving credit facility of \$85.0 million, principal payments on long-term debt of \$13.3 million, repurchase of shares for payroll tax withholding, net of proceeds from stock option exercises of \$7.5 million and distributions to noncontrolling partners in joint ventures of \$1.0 million, offset by \$13.2 million of contributions from noncontrolling partners in joint ventures.

We had total available cash and cash equivalents of \$99.6 million \$77.3 million and \$97.6 million \$100.1 million at **September 30, 2023** **March 31, 2024** and **December 31, 2022** **December 31, 2023**, respectively, of which approximately \$8.5 million \$13.5 million and \$3.7 million \$11.3 million was held by our foreign subsidiaries, respectively. Our strategic plan does not require the repatriation of foreign cash in order to fund our operations in the U.S.

Desert Hills Litigation

As described in more detail in Note **12** **10** – Commitments and Contingencies in the accompanying notes to our consolidated financial statements, on October 30, 2023, we entered into settlement agreements in connection with the Cases. The settlement agreements were approved by the District Court in December 2023 and fully resolve each of the Cases which are subject with no admission of liability or wrongdoing by us. On January 19, 2024, pursuant to approval by the District Court. We currently intend to pay the aggregate cash settlement of \$400.0 million with a combination of insurance proceeds, cash on hand and our existing credit lines. The settlement amounts must be paid within 30 days of the District Court's approval terms of the settlement agreements.

Though agreements, we expect the payment of the settlement amounts to have a material impact on our liquidity, we believe existing cash on hand, cash flows from operations and the availability under our revolving line of credit will be sufficient to meet our expected liquidity needs during the next 12 months and beyond.

Credit Facility

We entered into a credit agreement establishing a new Credit Facility on March 17, 2021. The Credit Facility provides for a \$600.0 million Revolving Facility and a \$425.0 million Term Loan Facility, with each maturing on March 17, 2026. The Revolving Facility further provides for (i) up to \$20.0 million which may be utilized for the issuance of letters of credit and (ii) the availability paid an aggregate amount of

\$400.0 million in exchange for the release and discharge of all claims arising from, relating to, concerning or with respect to all harm, injuries or damages asserted or that may be asserted in the future.

Credit Facility

On March 17, 2021, we entered into the Credit Facility, which provides for a swingline facility \$600.0 million Revolving Facility and a Term Loan Facility in an initial principal amount of \$425.0 million, each maturing on March 17, 2026. The Revolving Facility further provides for a \$20.0 million subfacility for the issuance of letters of credit.

As a part of the closing of the Credit Facility on March 17, 2021, we (i) refinanced and terminated our prior credit facilities under which we may borrow up to \$20.0 million, an amended and restated credit agreement, dated as of December 31, 2012 and (ii) financed the redemption of all of our outstanding 5.625% Senior Notes due 2023.

On March 30, 2023, we entered into the First Amendment. The First Amendment, which replaced LIBOR as the reference rate applicable to borrowings under the Credit Facility with Adjusted Term SOFR. Borrowings After giving effect to the First Amendment, borrowings under the Credit Facility bear interest at a rate equal to, at our option, either (a) a base rate determined by reference to the highest of (i) the federal funds rate plus 0.50%, (ii) the prime rate of Bank of America or (iii) Adjusted Term SOFR for plus a one month interest period or (b) Adjusted Term SOFR, in each case plus an applicable margin that varies according to our total leverage ratio from 0.375% to 1.250% in the case of base rate loans and ranging from 1.375% to 2.250% or (ii) a base rate plus a margin ranging from 0.375% to 1.250%, in the each case, of Adjusted Term SOFR loans. depending on our consolidated total net leverage ratio. In addition, an unused fee that varies according to our consolidated total net leverage ratio ranging from 0.200% to 0.350% is payable quarterly in arrears based on the average daily undrawn portion of the commitments in respect of the Revolving Facility.

During The interest rates and the nine months ended September 30, 2023 unused line fee on unused commitments related to the Credit Facility are based upon the following pricing tiers:

Pricing Tier	Consolidated Total Net		Commitment		
	Leverage Ratio	SOFR Loans	Base Rate Loans	Fee	
1	≥ 4.50:1.0	2.250 %	1.250 %	0.350 %	
2	<4.50:1.0 but ≥ 3.75:1.0	2.000 %	1.000 %	0.300 %	
3	<3.75:1.0 but ≥ 3.00:1.0	1.750 %	0.750 %	0.250 %	
4	<3.00:1.0 but ≥ 2.25:1.0	1.500 %	0.500 %	0.200 %	
5	<2.25:1.0	1.375 %	0.375 %	0.200 %	

On January 18, 2024, we borrowed \$40.0 million on entered into the Revolving Facility and repaid \$35.0 million Second Amendment, which provides for the incurrence of \$350.0 million of Incremental Term Loans. Such

Incremental Term Loans are structured as an increase of the balance outstanding. We had \$516.5 million of availability Term Loan Facility. The maturity date, the leverage-based pricing grid, mandatory prepayment events and other terms applicable to the Incremental Term Loans are substantially identical to those applicable to the initial \$425.0 million term loans incurred under the Revolving Facility and had standby letters of credit outstanding of \$3.5 million related Term Loan Facility. After giving effect to security for the payment of claims required by our workers' compensation insurance program at September 30, 2023.

The Incremental Term Loans, the Credit Facility requires quarterly term loan principal repayments for the Term Loan Facility of \$5.3 million approximately \$15.4 million for December 31, 2023 to March 31, 2024, \$8.0 million for each quarter ending from June 30, 2024 to March 31, 2025 and \$10.6 million \$20.5 million for each quarter ending from June 30, 2025 to December 31, 2025, with the. The remaining outstanding principal balance of the Term Loan Facility is due on the maturity date of March 17, 2026.

We have the ability to increase the amount of the Senior Facilities, Credit Facility, which may take the form of increases to the Revolving Facility or the Term Loan Facility or the issuance of the one or more Incremental Facilities, upon obtaining additional commitments from new or existing lenders and the satisfaction of customary conditions precedent for such Incremental Facilities. Such Incremental Facilities may not exceed the sum of (i) the greater of \$480.0 million and an amount equal to 100% of our Consolidated EBITDA (as defined in the Credit Facility), Incremental Fixed Basket, and (ii) additional amounts that would not cause the Consolidated Senior Secured Net Leverage Incremental Ratio (as defined Basket. The Incremental Term Loans were incurred in reliance on the Credit Facility) to exceed 3.5 to 1.0. Incremental Ratio Basket, leaving the full amount of the Incremental Fixed Basket available for any future Incremental Facilities.

Subject to certain exceptions, substantially all of our existing and subsequently acquired or organized direct or indirect wholly-owned U.S. subsidiaries are required to guarantee the repayment of our obligations under the Credit Facility. We and such guarantor subsidiaries have granted a security interest on substantially all personal property assets as collateral for the obligations under the Credit Facility.

The interest rates and the unused line fee on unused commitments related to the Senior Facilities are based upon the following pricing tiers:

Pricing Tier	Consolidated Total Net Leverage Ratio	Term SOFR Loans, SOFR		
		Daily Floating Rate Loans and Letter of Credit Fees	Base Rate Loans	Commitment Fee
1	≥ 4.50:1.0	2.250 %	1.250 %	0.350 %
2	<4.50:1.0 but ≥ 3.75:1.0	2.000 %	1.000 %	0.300 %
3	<3.75:1.0 but ≥ 3.00:1.0	1.750 %	0.750 %	0.250 %
4	<3.00:1.0 but ≥ 2.25:1.0	1.500 %	0.500 %	0.200 %
5	<2.25:1.0	1.375 %	0.375 %	0.200 %

The Credit Facility contains customary representations and affirmative and negative covenants, including limitations on our ability and our subsidiaries' ability to incur additional debt, grant or permit additional liens, make investments and

acquisitions, merge or consolidate with others, dispose of assets, pay dividends and distributions, pay junior indebtedness and enter into affiliate transactions, in each case, subject to customary exceptions. In addition, the Credit Facility contains financial covenants requiring us on a consolidated basis to maintain, as of the last day of any consecutive four fiscal quarter period, a consolidated total net leverage ratio of not more than 4.5 to 1.0 (which may be increased to 5.0 to 1.0 for a period of up to four consecutive fiscal quarters following the consummation of certain material acquisitions) and an interest coverage ratio of at least 3.0 to 1.0. The Credit Facility also includes events of default customary for facilities of this type and upon the occurrence of any such event events of default, among other things, all

24

outstanding loans under the Senior Facilities Credit Facility may be accelerated, the lenders' commitments may be terminated, and/or the lenders may exercise collateral remedies. At September 30, 2023 March 31, 2024, we were in compliance with all financial covenants.

28

During the three months ended March 31, 2024, we borrowed \$160.0 million on the Revolving Facility and repaid \$15.0 million of the balance outstanding. During the three months ended March 31, 2023, we borrowed \$40.0 million on the Revolving Facility. We had \$371.5 million of availability under the Revolving Facility and had standby letters of credit outstanding of \$3.5 million related to security for the payment of claims required by our workers' compensation insurance program at March 31, 2024.

Senior Notes

5.500% Senior Notes due 2028

On June 24, 2020, we issued \$450.0 million of 5.500% Senior Notes. The 5.500% Senior Notes mature on July 1, 2028, and bear interest at a rate of 5.500% per annum, payable semi-annually in arrears on January 1 and July 1 of each year, commencing on January 1, 2021.

5.000% Senior Notes due 2029

On October 14, 2020, we issued \$475.0 million of 5.000% Senior Notes. The 5.000% Senior Notes mature on April 15, 2029, and bear interest at a rate of 5.000% per annum, payable semi-annually in arrears on April 15 and October 15 of each year, commencing on April 15, 2021.

The indentures governing the Senior Notes contain covenants that, among other things, limit our ability and the ability of our restricted subsidiaries to: (i) pay dividends, redeem stock or make other distributions or investments; (ii) incur

additional debt or issue certain preferred stock; (iii) transfer or sell assets; (iv) engage in certain transactions with affiliates; (v) create restrictions on dividends or other payments by the restricted subsidiaries; (vi) merge, consolidate or sell substantially all of our assets; and (vii) create liens on assets.

The Senior Notes issued by us are guaranteed by each of our subsidiaries that guarantee our obligations under the Credit Facility. The guarantees are full and unconditional and joint and several.

We may redeem the Senior Notes at our option, in whole or part, at the dates and in the amounts set forth in the applicable indentures.

Supplemental Guarantor Financial Information

We conduct substantially all of our business through our subsidiaries. The Senior Notes are jointly and severally guaranteed on an unsecured senior basis by all of our subsidiaries that guarantee our obligations under the Credit Facility. The summarized financial information presented below is consistent with our condensed consolidated financial statements, except transactions between combining entities have been eliminated. Financial information for our combined non-guarantor entities has been excluded pursuant to SEC Regulation S-X Rule 13-01. Presented below is condensed financial information for our combined wholly-owned subsidiary guarantors at September 30, 2023 March 31, 2024 and December 31, 2022 December 31, 2023, and for the nine three months ended September 30, 2023 March 31, 2024.

Summarized balance sheet information (in thousands):

	September 30,		December 31,		
	2023	2022	March 31, 2024	December 31, 2023	
Current assets	\$ 537,028	\$ 396,553	\$ 484,365	\$ 442,813	
Property and equipment, net	1,595,342	1,517,893	1,681,224	1,656,941	
Goodwill	2,105,563	2,105,227	2,140,627	2,105,563	
Total noncurrent assets	3,977,033	3,921,336	4,097,017	4,043,891	
Current liabilities	789,090	345,606	461,731	827,648	
Long-term debt	1,349,954	1,364,541	1,794,296	1,342,548	
Total noncurrent liabilities	1,589,730	1,629,750	1,978,103	1,503,345	
Redeemable noncontrolling interests	—	—	—	—	
Total equity	2,135,241	2,342,533	2,141,548	2,155,711	

Summarized operating results information (in thousands):

	Nine Months Ended
	September 30, 2023
Revenue	\$ 1,909,885
Loss before income taxes	(141,230)
Net loss	(101,340)
Net loss attributable to Acadia Healthcare Company, Inc.	(101,340)

29

	Three Months Ended March 31,
	2024
Revenue	\$ 652,725
Income before income taxes	79,905
Net income	64,400
Net income attributable to Acadia Healthcare Company, Inc.	64,400

Contractual Obligations

The following table presents a summary of contractual obligations at **September 30, 2023** **March 31, 2024** (in thousands):

	Payments Due by Period					Payments Due by Period				
	More					Less Than				
	Less		Than			1 Year		More Than		
	Than	1-3	3-5	5	Total	1 Year	1-3 Years	3-5 Years	5 Years	Total
	1 Year	Years	Years	Years	Total	1 Year	1-3 Years	3-5 Years	5 Years	Total
Long-term debt	106	570	540	516	1,73					
(a)	,47	,56	,81	,56	4,41					
	\$ 5	\$ 1	\$ 3	\$ 2	\$ 1	\$ 173,317	\$ 1,025,775	\$ 528,438	\$ 504,688	\$ 2,232,218
Operating lease	32,	51,	27,	58,	170,					
liabilities (b)	855	708	407	978	948	33,644	49,235	27,314	72,074	182,267
Finance lease		2,1	2,1	21,	26,3					
liabilities	990	70	78	005	43	1,031	2,178	2,178	20,460	25,847

Total obligations	140	624	570	596	1,93						
and	,32	,43	,39	,54	1,70						
commitments	\$ 0	\$ 9	\$ 8	\$ 5	\$ 2	\$ 207,992	\$ 1,077,188	\$ 557,930	\$ 597,222	\$ 2,440,332	

(a) Amounts include required principal and interest payments. The projected interest payments reflect the interest rates in place on our variable-rate debt at **September 30, 2023** **March 31, 2024**.

(b) Amounts exclude variable components of lease payments.

Critical Accounting Policies

There have been no material changes in our critical accounting policies at **September 30, 2023** **March 31, 2024** from those described in our Annual Report on Form 10-K for the year ended **December 31, 2022** **December 31, 2023**.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Interest Rate Risk

Our interest expense is sensitive to changes in market interest rates. Our long-term debt outstanding at **September 30, 2023** **March 31, 2024** was composed of **\$915.5 million** **\$916.3 million** of fixed-rate debt and **\$434.5 million** **\$939.5 million** of variable-rate debt with interest based on Adjusted Term SOFR plus an applicable margin. Based on our borrowing level at **September 30, 2023** **March 31, 2024**, a hypothetical 1% increase in interest rates would decrease our pretax income on an annual basis by approximately **\$4.3 million** **\$9.4 million**.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, our management conducted an evaluation, with the participation of our chief executive officer and chief financial officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on this evaluation, our chief executive officer and chief financial officer have concluded that our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to management, including our chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting during the three months ended **September 30, 2023**, **March 31, 2024** that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

Information with respect to this item may be found in Note 12 10 – Commitments and Contingencies in the accompanying notes to our consolidated financial statements of this Quarterly Report on Form 10-Q, which information is incorporated herein by reference.

Item 1A. Risk Factors

In addition to the other information set forth in this report, an investor should carefully consider the factors discussed in Part I, "Item 1A. Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2022 and Part II, "Item 1A. Risk Factors" December 31, 2023. The risks described in the Company's Quarterly Annual Report on Form 10-Q 10-K for the quarter year ended June 30, 2023 (collectively, December 31, 2023, are not the "Periodic Reports"). As of only risks facing the date of this Quarterly Report on Form 10-Q, there have been no material changes to the risk factors disclosed in the Periodic Reports. Company. Additional risks and uncertainties not currently known to management or that management currently deems immaterial also may materially, adversely affect the Company's business, financial condition, operating results or cash flows.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds and Issuer Repurchases of Equity Securities

During the three months ended September 30, 2023 March 31, 2024, the Company withheld shares of Company common stock to satisfy employee minimum statutory tax withholding obligations payable upon the vesting of restricted stock, as follows:

Period	Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs	Purchased as Part of Publicly Announced Plans or Programs	
			Total Number of Shares Purchased	Average Price Paid per Share
July 1 - July 31	6,082	—	—	\$ 76.71

August 1 - August 31	3,542	76.89	—	—
September 1 - September 30	4,766	70.48	—	—
Total	14,390			

Period			Total Number of Shares	Maximum Number
			Purchased as	of Shares that
	Total Number of Shares	Average Price	Announced	Under
Purchased	Paid per Share	Plans or Programs	the Plans or Programs	
January 1 - January 31	—	\$ —	—	—
February 1 - February 29	53,344	84.00	—	—
March 1 - March 31	16,967	79.88	—	—
Total	70,311			

Item 5. Other Information

From time to time, certain of our executive officers and directors may enter into, amend or terminate written trading arrangements pursuant to Rule 10b5-1 of the Securities Exchange Act of 1934 or otherwise. During the three months ended **September 30, 2023** **March 31, 2024**, none of the **Company's** directors or officers adopted or terminated any Rule 10b5-1 trading arrangement or **non-Rule** **non- Rule** 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K).

31

27

Item 6. Exhibits

Exhibit No. Exhibit Description

3.1 [Amended and Restated Certificate of Incorporation, as amended..\(1\)](#)

3.2	Amended and Restated Bylaws of the Company, as amended. (1)
10.1	First Amendment No. 2, dated as of January 18, 2024, to Employment the Company's Credit Agreement, dated as of July 6, 2023, by and between Acadia Management Company, Inc. and Brian Farley, March 17, 2021. (2)
10.2	Separation and Transition Agreement, dated July 5, 2023, between Acadia Management Company, LLC. and Chris Howard. (3)
10.3	Transition Agreement, dated July 5, 2023, by and between Acadia Management Company, LLC and David Duckworth. (3)
22	List of Subsidiary Guarantors and Issuers of Guaranteed Securities. (4)(3)
31.1*	Certification of the Chief Executive Officer of the Company pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*	Certification of the Chief Financial Officer of the Company pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32*	Certification of Chief Executive Officer and Chief Financial Officer of the Company pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS**	Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the inline Inline XBRL document.
101.SCH**	Inline XBRL Taxonomy Extension Schema Document with embedded Linkbase Documents.
101.CAL**	Inline XBRL Taxonomy Calculation Linkbase Document.
101.DEF**	Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB**	Inline XBRL Taxonomy Label Linkbase Document.
101.PRE**	Inline XBRL Taxonomy Presentation Linkbase Document.
104	The cover page from the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 March 31, 2024 , has been formatted in Inline XBRL.

(1) Incorporated by reference to exhibits filed with the Company's Current Report on Form 8-K filed May 25, 2017 (File No. 001-35331).

(2) Incorporated by reference to exhibits filed with the Company's [Quarterly](#) [Current](#) Report on Form [10-Q](#) [8-K](#) filed for the quarter ended [June 30, 2023](#) [January 19, 2024](#) (File No. 001-35331).

(3) Incorporated by reference to exhibits filed with the Company's Current Report on Form 8-K filed July 5, 2023 (File No. 001-35331).

(4) Incorporated by reference to exhibits filed with the Company's Annual Report on Form 10-K for year ended [December 31, 2022](#) [December 31, 2023](#) (File No. 001-35331).

* Filed herewith.

** The XBRL related information in Exhibit 101 to this quarterly report on Form 10-Q shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability of that section and shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document.

3228

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Acadia Healthcare Company, Inc.

By: /s/ Heather Dixon
Heather Dixon
Chief Financial Officer

Dated: November 3, 2023 May 2, 2024

3329

Exhibit 31.1

**CERTIFICATION OF CEO PURSUANT TO
RULE 13a-14(a)/15d-14(a), AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Christopher H. Hunter, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Acadia Healthcare Company, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 3, 2023 May 2, 2024

/s/ Christopher H. Hunter

Christopher H. Hunter

Chief Executive Officer and Director

Exhibit 31.2

**CERTIFICATION OF CFO PURSUANT TO
RULE 13a-14(a)/15d-14(a), AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Heather Dixon, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Acadia Healthcare Company, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

- All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
- Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 3, 2023 May 2, 2024

/s/ Heather Dixon

Heather Dixon
Chief Financial Officer

Exhibit 32

**CERTIFICATIONS OF CEO AND CFO PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q of Acadia Healthcare Company, Inc. (the "Company") for the quarterly period ended September 30, 2023 March 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Christopher H. Hunter, Chief Executive Officer of the Company, and I, Heather Dixon, Chief Financial Officer of the Company, each certify, for the purpose of complying with 18 U.S.C. Section 1350 and Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the "Exchange Act"), as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

- The Report fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

Date: November 3, 2023 May 2, 2024

/s/ Christopher H. Hunter

Christopher H. Hunter

Chief Executive Officer and Director

/s/ Heather Dixon

Heather Dixon

Chief Financial Officer

DISCLAIMER

THE INFORMATION CONTAINED IN THE REFINITIV CORPORATE DISCLOSURES DELTA REPORT™ IS A COMPARISON OF TWO FINANCIALS PERIODIC REPORTS. THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORT INCLUDING THE TEXT AND THE COMPARISON DATA AND TABLES. IN NO WAY DOES REFINITIV OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED IN THIS REPORT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S ACTUAL SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.

©2024, Refinitiv. All rights reserved. Patents Pending.